n/a
full list rate price target
earn report pleas see tabl
initi posit view
initi coverag med-tech sector posit view past five
year med-tech fundament improv evidenc acceler sale
growth rate view innov trend continu improv thank part
favor fda environ industri structur oligopoli favor
conduc profit growth given current dynam expect
med-tech market grow forese futur believ recent
increas pe multipl warrant given improv fundament look ahead
believ rel pe multipl least maintain
physician survey help inform view conduct two
survey transcathet aortic valv orthopedics/robotic-assist surgeri
physician expect strong volum growth tavr go forward expect use new
product includ boston scientif lotu abbott portico valv orthoped
surgeon expect healthi volum growth hip knee increas adopt
robotic-assist system stryker mako lead way
barclay hospit survey provid insight outlook healthcar
servic team survey hospit system respond expect inpati volum
acceler stabl capital-expenditure trend favor med-tech
view stock initi coverag stock follow rate
overweight expect innov diversifi growth stori continu
outperform abbott diversifi growth new product tailwind boston
scientif consensu long good reason diversifi growth
equal weight avano chart new better cours
turnaround success stock hill-rom lack convict sale
acceler put take leav us sidelin
underweight dont expect signific downsid current level
expect stock greater earn risk under-perform med-tech group
baxter long-term outlook good near-term ep risk edward
lifesci ew tavr competit ahead second act tmvr/r way
zimmer biomet transform need like take signific time
word caution approach earn would remiss
mention could near-term headwind group upcom
earn season look ahead believ street estim may
bit high mani across sector due varieti reason includ stronger us
dollar reinvest spend case higher tax rate manag
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn estim report
co
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
initi med-tech sector posit industri view
take stock
med-tech larg divers sector
med-tech stock histori out-performance
past two year medtech perform notabl
innov trend fda environ favor
evolv still favor industri dynam
global demograph trend favor
environ conduc profit growth
valuat current multipl seem appropri us
risk posit industri view
diversifi growth new product tailwind initi overweight
chart new better cours ip sale initi equal weight
long-term outlook near-term ep risk initi underweight
steadi perform market expect seem fair initi equal weight
consensu long reason initi overweight
turnaround success stock initi equal weight
tavr competit ahead second act way initi under-perform
lack convict sale acceler initi equal weight
valuat still attract despit recent initi overweight
diversifi growth stori remain intact initi overweight
con leav us sidelin initi equal weight
transform like take signific time initi underweight
survey conclus stock implic
survey conclus stock implic
initi med-tech sector posit industri view
medic suppli devic med-tech sector includ number compani
manufactur healthcar product rang basic gauz band-aid
advanc left ventricular assist devic implant defibril transcathet
heart valv product often sold hospit well healthcar
facil use treat patient suffer varieti condit estim
world-wide market med-tech product roughli billion
past five year med-tech stock outperform broader market
sector move own wide own space view
attribut out-performance improv underli fundament acceler
sale growth rate improv innov trend along industri consolid
year-to-d basi octob large-cap stock outperform
broader market healthcar equip suppli index versu
initi coverag med-tech sector posit industri view med-tech
industri fundament improv recent year expect remain
favor expect coverag univers grow sale least mid-singl digit
combin oper financi leverag grow ep double-digit
pace reason believ current multipl least maintain
view sector
take stock
initi coverag stock within medic suppli devic sector
take stock
besid valuat could chang view upcom catalyst
rate share overweight believ abbott
favor product geograph mix see
medic devic busi key driver growth go
forward abbott host new er product
allow sustain above-averag sale growth
transcathet mitral valv sever medic
devic also believ low-double-digit ep growth
constant currenc basi sustain view
stock worthi premium valuat
rate share equal weight view sale
 ip posit catalyst believ manag
right strategi redeploy ip proce
medic devic growth initi howev
stock signific upsid believ
current price larg captur success reach
long-rang goal outlin june analyst day
rate share underweight believ baxter
pois drive sale growth acceler new
product launch long-rang plan year
compani like face headwind
cyclophosphamid brevibloc new product
limit due clari fda warn letter
pharma headwind along like higher tax rate
fx headwind could pressur near-term earn
outlook believ consensu ep expect
favor view abbott
predic belief sustain above-
averag sale growth rate extent abbott
unabl achiev growth due slower
uptak pipelin failur greater competit
could chang view abbott signific
exposur emerg market
given fx rate could pressur ep said
focus underli oper
us construct stock
would like gain greater confid
compani abil deliv mid-to-high single-
digit sale growth longer term
achiev cost synergi strategi
could becom cautiou extent
sale growth slow margin stori
seem obtain play
concern street expect may
high main reason underweight
rate us construct
stock would like confid
acceler top line particularli
pharmaceut busi also could
construct believ street/market
expect lower
take stock
besid valuat could chang view upcom catalyst
continu success
integr bard
achiev plan synergi though market
alreadi appreci base success
carefus think street ep forecast may
slightli high given current foreign exchang rate
concern street expect may
high main reason equal weight
rate extent street expect
could becom
construct also could construct
extent clariti pipelin
sustain growth
guidanc
rate share overweight believ stock
consensu long good reason believ boston
scientif one highest sustain sale growth
profil larg cap med-tech compani
number new product across busi
segment provid high-single-digit sale
growth key new er product includ
lotu acur
peripher intervent product urolog product
also expect double-digit ep growth continu
success execut turnaround
seem well-posit deliv mid-singl digit sale
double-digit ep growth howev believ
valuat appropri reflect outlook
also concern predict
growth worri quarter-to-quart volatil
see downsid risk consensu ep estim
higher tax rate
could becom cautiou see sign
competit bd main product categori
and/or slowdown legaci bard busi
favor view larg predic
belief sustain above-averag sale
growth rate extent boston scientif
unabl achiev due slower uptak
pipelin failur greater competit could
chang view
guidanc
could becom construct stock
extent higher convict
compani abil sustain least mid-single-
digit sale growth see path forward
signific improv margin profil
guidanc
could becom cautiou extent
larger player turn
sale growth outlook becom temper
take stock
besid valuat could chang view upcom catalyst
rate ew share underweight edward current
turn view support tavr
survey tavr market like becom
competit go forward new entrant edward
sale growth like slow due competit
believ consensu sale estim optimist
also expect edward invest transcathet mitral
valv tmvr/r opportun consensu
ep estim may also high believ tmvr/r
repres potenti second act like
crowd space believ stock risk/reward less
favor given premium pe valuat
could becom construct stock
edward abl defend transcathet
aortic valv busi survey
suggest competit see delay
unabl receiv regulatori approv and/or
higher level convict edward
probabl success transcathet mitral
low risk trial result
updat tmvr/r
rate share equal weight believ
compani may continu struggl increas core
sale growth may necessari
ep estim seem reason think
street may littl high view
valuat seem fair outlook
number new product across busi
allow sustain mid-single-digit growth
expect leverag provid least
appreci share see stock valuat pe
peer still attract
guidanc
could becom construct
share extent increas confid
compani abil acceler sale
growth rate either new product
acquisit
could cautiou extent
sign weak hospit capit
equip market and/or sign
favor view part due belief
sustain mid-single-digit sale growth
achiev oper margin object
unabl achiev
expect sale growth due slower uptak
pipelin failur greater competit could
chang view moreov extent
greater price pressur fx pressur could
inhibit compani abil expand margin
could also chang view
corevalv data
take stock
besid valuat could chang view upcom catalyst
rate share overweight believ
sustain above-sector revenu growth profil see
multipl driver across three
busi
deliv margin commit goal
least annual drive least ep
growth given durabl growth believ
premium valuat sustain warrant
acquisit neotract urolift vascular solut
vsi help sale growth outlook howev
core growth rate struggl improv ep
estim street believ fx
rise interest rate headwind believ stock
fairli valu current level
appoint bryan hanson ceo posit catalyst
chang believ orchestr turnaround
howev stock see signific appreci
believ transform necessari could take
competit posit knee impact like
materi believ earn outlook
zimmer
like remain pressur
manag seek invest futur growth
ep estim street
could becom cautiou
extent sale growth rate deceler
integr acquisit
pend
acquisit
could becom construct stock
extent greater confid
outlook core busi and/or greater
confid upsid scenario urolift
could becom cautiou share
urolift sale disappoint view product
key driver growth stock valu
could also cautiou extent
could becom construct
share extent confid
sustain higher rate sale growthwheth
new product like
portfolio manag extent
manag
compani
 could result favor
view stock could also
construct earn growth rate
compani could improv sooner expect
jan result
guidanc
guidanc
marketpricepric epsbarclay adjust ep esttr consensu ep estsp ratio onrel pept petickercompanycap ptdiv cap compani billion market cap market cap weight compani million market cap market cap weight definit ow overweight ew equal weight uw underweightenterprisenetdebt tobarclay sale estimate million cagrbarclay ebitda estimate mil ev sale estimate ev ebitda estimate tickercompanyvalu debt cap compani billion market cap ev weight compani million market cap market cap weight barclay medic suppli devic
med-tech larg divers sector
medic suppli devic med-tech sector includ number compani
manufactur healthcar product rang basic gauz band-aid
advanc implant defibril transcathet heart valv product
often sold hospit healthcar facil use treat patient
suffer varieti condit
estim world-wide market med-tech product roughli billion
largest submarket identifi figur largest player figur
pf bard
roch diagnost
novarti alcon
olympu medic
sale estim calendar compani
report currenc translat usd
use averag exchang rate year
med-tech stock histori out-performance
med-tech industri use healthcar equip suppli index benchmark outperform broader market past
year attribut out-performance mainli new product gener increment revenu and/or earn growth recent year
consolid trend respect period under-perform period sever matter affect stock sector cardio
recal doj orthopaed investig wherea period health reform advers impact economi overal growth rate weigh
rel perform shown figur perform med-tech outpac broader healthcar index notabl sinc end view
rel attract med-tech enhanc drug price rhetor presidenti elect campaign
 healthcar equip suppli healthcar indic price perform
index
figur illustr annual price perform med-tech healthcar sector market individu stock within med-tech univers
period out-performance rel highlight seen recent year stock outperform market
medic suppli devic current jude first period public trade price chang calcul first avail when-issu price last period public trade price chang calcul use last trade date year barclay medic suppli devic
past two year medtech perform
past two year medtech rel out-performance notabl shown
figur healthcar equip suppli index outperform broader
healthcar index well index year-to-d basi
med-tech price perform year-to-d
within healthcar shown figur med-tech top perform outperform
pharma provid servic
rel price perform
date hc equip suppliess hc barclay medic suppli devic
shown figur med-tech outperform consum
stapl stock past two year
rel price perform med-tech pharma consum stapl
figur illustr individu stock perform coverag univers
shown stock outperform overal market
 healthcar equip suppli stock year-to-d price perform
initi coverag med-tech sector posit view med-tech industri
fundament improv recent year evidenc acceler sale growth
rate look ahead continu see sever posit trend continu
bode well sector fundament background believ multipl
least maintain histor averag
med-tech composit annual chang sale
view sector
innov trend favor fda environ view innov
trend improv across sector evidenc higher number origin
pma de novo request approv fda environ becom friendlier
toward devic compani evidenc faster review time willing
adapt trial design part aid innov trend
industri structur consolid trend industri structur favor
conduc profit growth year compani consolid
excess cash mani compani order continu drive top line growth
demograph global demograph trend name age popul provid
backdrop steadi volum growth
washington polici unlik area healthcar name pharma
pharma suppli chain med-tech industri polit
spotlight part one matter receiv attent medic
devic excis tax bipartisan support repeal
reimburs reimburs perspect signific chang
abound asid broad effort shift value-bas payment scheme
regard believ med-tech compani start posit
succeed environ mani start initi econom base studi
incorpor value-ori approach effort
innov trend fda environ favor
innov lifeblood med-tech
view innov lifeblood med-tech industri figur illustr
major mileston med-tech innov trend across med-tech univers
eb flow period meaning new product approv
other
timelin major med-tech mileston
estim med-tech market spend around revenu research
develop figur illustr spend across med-tech compani
divis avail
 spend percent sale recent fiscal year
figur illustr number origin pma de novo applic approv
calendar year origin pma pre-market approv applic class
medic devic de novo approv medic devic legal
market predic devic gener and/or special control provid reason
assur safeti effect intend use figur illustr
number clearanc grant calendar year clearanc
grant devic shown least safe effect substanti
equival legal market devic subject pma typic class
ii devic lower tech
believ uptick origin pma de novo approv bode well revenu
outlook sector
number origin pma approv de novo request grant
number clearanc grant
favor fda environ polici help innov
view fda becam increasingli conserv sever
notabl recal includ merck recal vioxx late guidant defibril
recal well safeti concern aris around first gener drug-
elut stent stent thrombosi believ increas conservat result
lengthen regulatori review process exampl submiss
addit inform request first fda review cycl increas
second review cycl
averag time mdufa decis pma submiss increas
period number origin submiss major defici letter
first fda review cycl increas
begin sever legisl action chang landscap help revers
trend major statist return level
juli food drug administr safeti innov act fdasia
sign law updat mani process procedur bring new
healthcar product market key provis within fdasia meaning
impact medic devic industri medic devic user fee amend
mdufa fda could collect million user fee
five year allow fda increas headcount meet certain
perform goal second section de novo provis creat
altern pathway de novo devic remov need submit
submiss prior de novo request
april fda publish expedit access pre-market approv de
novo medic devic intend unmet medic need life threaten
irrevers debilit diseas condit expedit access pathway eap
eap allow earlier interact review fda prioriti review
post market data collect well looser requir around clinic evid
manufactur review pma submiss provid lenienc de novo
decemb centuri cure act sign law includ
breakthrough devic program design speed review innov medic
devic program expand expedit access pathway program make
submiss elig along pma de novo
believ favor fda environ help spur innov
believ industri focus meaning innov oppos
increment advanc purchas hospit becom critic
product use
european regul trend opposit direct
us regulatori environ eas european market came scrutini
lack uniform vari level expertis among variou notifi bodi
respons devic evalu tighter regulatori control subsequ propos
lead declin number notifi bodi due determin lack
expertis brexit could potenti decreas certif
capac addit well declin notifi bodi lead
increas wait time obtain ce mark regulatori requir also becom
complex rigor clinic evid post market data collect
standard among chang chang caus medic
devic compani shift earli feasibl studi us versu eu earlier
trial histor taken place
list pma de novo approv sinc relev coverag univers
notabl pma de novo approv
descript intent use
eluvia drug-elut vascular stent system indic improv
lumin diamet treatment symptomat de-novo restenot
lesion nativ superfici femor arteri sfa and/or proxim poplit
arteri refer vessel diamet rvd rang mm
total lesion length mm
use abbott system abbott real-time indic
aid identifi acut myeloid leukemia aml patient
isocitr mutat treatment tibsovo
use endovascular treatment patient larg giant saccular
wide-neck fusiform intracrani aneurysm intern carotid arteri
lifepak defibril
approv lifepak defibril lifepak defibril lithium-
lifepak defibrillator/ monitor lifepak monitor/defibril
lifepak lithium-ion recharg batteri defibril use
 mode patient cardiopulmonari arrest
part
guardian connect system continu period monitor glucos level
provid clinician physiolog insight patient likelihood
futur hypotens event defin mean arteri pressur mmhg
least one minut durat associ hemodynam
qualit vitro test detect human papillomaviru
cervic specimen collect clinician use endocerv
brush/spatula combin broom place bd surepath vial
implant system
adult patient class ii pulmonari arteri hypertens
pah receiv intraven deliveri remodulin
bilater stimul subthalam nucleu stn treatment
patient moder advanc levodopa-respons parkinson diseas
pd adequ control medic
continu glucos monitor cgm devic indic
manag diabet person age older design
replac blood glucos test diabet treatment decis
percutan translumin angioplasti pta pre-dilat
treatment stenot lesion dysfunct nativ arterioven dialysi
fistula mm mm diamet mm length
 bard
part becton
provid short-term hemodynam support bridg transplant
bridg myocardi recoveri patient advanc refractori left
real-time use abbott indic
aid identifi acut myeloid leukemia aml patient isocitr
mutat treatment idhifa enasidenib
thoratec
part abbott
surgic valv replac diseas damag malfunct
nativ prosthet aortic valv
surgic heart valv provid short-term hemodynam support
bridg transplant bridg myocardi recoveri patient
use aid manag hematopoiet stem cell transplant
patient undergo anti-cytomegaloviru therapi
devic indic improv coronari lumin diamet patient
includ diabet mellitu symptomat ischem heart
diseas due de novo lesion length less equal mm nativ
coronari arteri refer vessel diamet mm mm
descript intent use
devic indic treatment atherosclerot lesion
common extern iliac arteri refer vessel diamet
mm mm lesion length mm
 bard
part becton
approv assur mri endur mri pacemak tendril mri lead
mri activ merlin pc programm softwar approv mr
part
amplatz pfo occlud devic indic percutan transcathet closur patent
foramen oval pfo reduc risk recurr ischem stroke
patient predominantli age year
cryptogen stroke due presum paradox embol
determin neurologist cardiologist follow evalu
exclud known caus ischem stroke
intend continu deliveri basal insulin user select rate
administr insulin bolus user select amount
manag type diabet mellitu person fourteen year age
older requir insulin well continu monitor
trend glucos level fluid skin
part
profession continu glucos monitor cgm devic indic
detect trend track pattern person age older
diabet intend use health care profession
restor blood flow neurovasculatur remov thrombu
treatment acut ischem stroke reduc disabl patient
persist proxim anterior circul larg vessel occlus smaller
core infarct first receiv intraven tissu plasminogen
surgic valv indic replac diseas damag
malfunct nativ prosthet aortic valv
devic indic improv coronari lumin diamet patient
ischem heart diseas due de novo nativ coronari arteri lesion
mm mm diamet lesion mm length
cgm system
record use either enlit sensor sof-sensor
intend continu record interstiti glucos level person
diabet mellitu inform intend supplement replac
indwel month treatment benign biliari strictur
secondari chronic pancreat
test detect delet probe target via fluoresc situ
hybrid fish peripher blood specimen patient b-cell
stimuli radiofrequ ablat sustain recurr type atrial
flutter patient age older
devic indic spinal column stimul via epidur intra-
spinal lead access dorsal root ganglion aid manag
moder sever chronic intract pain lower limb adult
patient complex region pain syndrom crp type ii
part
longer
tabl detail expect approv key product coverag univers
continu glucos monitor system option arm
drug-coat balloon treat superfici femor arteri
becton dickinson wearabl patch pump type ii diabet
gener transcathet aortic valv enhanc seal
mri compat version crt-p last remain mri product gap
rf ablat balloon atrial fibril
drug-coat balloon treat superfici femor arteri
evolv still favor industri dynam
med-tech industri competit dynam chang past two decad
past medic devic manufactur benefit littl price transpar
financi misalign decis maker purchas physician choos
product use wherea hospit would ultim pay product
fragment hospit insur market gener benefit fee-for-
servic model incentiv volum util
past two decad lot chang price transpar improv
pressur averag sell price product categori hospit sought
greater financi align physician move toward physician-
employ model result physician decis make devic use
lessen directli associ valu hospit health insur
industri undergon signific consolid lastli effort underway move
away fee-for-servic toward outcom value-bas design
chang affect way med-tech manufactur oper result
financi pressurewheth lower unit volum lower sell price
inabl drive favor product mix
med-tech industri stood still adapt chang environ like
healthcar sector med-tech industri also consolid improv
competit posit growth prospect shown figur
sever signific transact across med-tech space mani med-tech market
oligopoli posit implic sector econom
regulatori agenc fda etc med-tech manufacturerspurchasershospitalsphysician officeslaboratoriespatientsdirect salesdistributorultim payorsgovern us center medicar medicaid servic privat insur companiesemployerspati barclay medic suppli devic
expect consolid continu across med-tech sector believ scale
becom increasingli import transact hospit also expect compani
continu pursu tuck-in technolog acquisit enhanc sale growth prospect
aforement said med-tech industri competit dynam remain
favor mani industri view demand new technolog remain high
albeit compani must demonstr greater econom valu past
med-tech manufactur focus develop product deliv
econom benefit market continu reward new technolog lastli still
remain financi misalign area purchas reimburs
decis benefit med-tech compani
popul world age life expect extend thank part
advanc medicin figur show percentag peopl
age older expect increas across globe
global age popul
 censu bureau intern data base decenni census nation popul project
age us popul
 censu bureau intern data base decenni census nation popul project
populationpopulationmillionsnumb popul total popul rh babi boomersturn barclay medic suppli devic
share popul age
oecd glanc oecd indic oecd publish pari
age popul like increas amount healthcar spend sever
studi shown individu spend healthcar expenditur later
year life includ spend relat medic technolog
rel lifetim per capita expenditur differ interv life tabl
cohort survivor year dollar
alemayehu berhanu kenneth warner lifetim distribut health cost
top five frequent all-list oper room procedur age group
number
procedur
age group
arthroplasti knee
laminctomi excis intervertebr disc
hip replac total partial
arthroplasti knee
hip replac total partial
laminctomi excis intervertebr disc
treatment fractur disloc hip
hip replac total partial
arthroplasti knee
agenc healthcar research qualiti ahrq center deliveri organ market
healthcar util project hcup hcupnet barclay research
socio-econom trend favor emerg market
emerg market repres opportun med-tech compani countri look
advanc healthcar system
environ conduc profit growth
expect med-tech sector grow rang forese futur
given environ exist today figur review outlook major
view market matur expect
modest growth go forward said
evolut leadless devic could repres upsid
expect market remain flat price
expect continu double-digit growth fuel
continu adopt technolog af
expect growth come increas
adopt lvad technolog improv
expect growth aortic well mitral valv
therapi next five year
expect continu adopt devic
treat patient stroke driven recent clinic
trial updat guidelin
expect market continu grow
doubl digit devic adopt increas
flat
insulin pump patch
expect unit volum increas partial
off-set price declin robot system
expect modest growth price pressur
expect modest growth driven mainli unit
expect growth driven continu
penetr new technolog
expect steadi growth driven increas
util modest price pressur
expect signific growth driven
introduct new technolog
expect continu growth insulin pump
therapi advanc
growth driven patient growth age popul
roch siemen abbott expect steadi growth compani roll next
gener system assay
figur illustr expect organ sale growth
compani next year
valuat current multipl seem appropri us
figur display histor absolut rel pe
composit med-tech stock seen period healthcar reform
effort multipl compress absolut rel basi past five
year absolut pe rel pe less multipl expand sector
trade histor averag believ current level appropri given
rel growth outlook believ sector fundament warrant
signific expans back level late early-to-mid given
secular chang industri believ pe expans past eight year
warrant reflect improv fundament
barclay med-tech composit rel pe histori
composit includ ew well guidant biomet covidien bard st jude medic trade
composit includ ew well guidant biomet covidien bard st jude medic trade
averag rel rel healthcar reform effortsobamahealthcar reform effortsaverag peclinton healthcar reform effortsobamahealthcar reform effort barclay medic suppli devic
figur illustr medtech multipl rel
healthcar sector well econom sector
healthcar sub-industry pe multipl
price octob
standard poor thomson reuter
 econom sector pe multipl
price octob
rel pe valuat multipl med-tech composit versu consum stapl composit
cross healthcar valuat comparison valu thomson reuter consensu estim
market price ony/i pe ratio onmarket price ony/i pe ratio ontickercompani namecap namecap medic suppli devicesagn nallergan intern compani dickinson pharmaceut industri scientif lifesci caretfx nteleflex group biomet hold hold plan compani nephew lifesci hold tool servicesdistributorsa nagil hold intern schein fisher scientif minor serviceslarg cap biopharmaceuticalslh nlaboratori corpor america diagnost script hold squibb care scienc itlli neli lilli co care servic barclay medic suppli devic
risk posit industri view
believ med-tech stock enjoy expand pe multipl attribut
improv fundament potenti risk posit industri view
healthcar reform effort histori show med-tech pe multipl significantli
compress period healthcar reform case earli
clinton healthcar reform effort well period
obama healthcar reform extent futur reform effort could
weigh pe multipl medicar repres signific payer mani procedur
use medic suppli devic medicar hospit insur trust fund cover
medicar part pay hospit home health servic follow hospit stay
skill nurs facil hospic care age disabl medicar
cover million peopl includ million age older
popul age increas number individu becom elig medicar
medicar board truste issu report year analyz project
medicar receipt expenditur accord truste hi tax incom
dedic revenu fall short hi expenditur futur year
report truste conclud hi trust fund meet either truste
test short-rang financi adequaci test long-rang close actuari balanc
effort reform medicar program add consider
reform occur near futur see futur medicar reform potenti
risk prospect med-tech industri stock also see healthcar reform
effort intern potenti risk well
innov trend fda/intern regulatori environ recent year
industri enjoy period favor fda polici believ foster
innov extent fda environ becom restrict and/or
review timelin extend innov trend could suffer innov lifeblood
med-tech support top line growth fda intern regulatori polici
impact innov could also advers impact sale growth rate
valuat multipl regulatori approv process europ medic devic
chang recent could impact time new product approv
price trend price med-tech industri gener neutral neg
across product area area experienc greatest price pressur tend
cardiovascular orthoped coronari stent price declin trend
manag devic seen price declin low-singl digit
orthoped implant extent price trend becom challeng due
pressur buyer hospit result reimburs dynam
could impact sale growth margin turn could weigh valuat
period
reimburs would character reimburs environ fairli
neutral today med-tech categori payor
aim limit use product major effort underway materi
chang way product reimburs would parallel dramat
chang like creation prospect payment pp diagnosi relat
group drg earli medpac view start evalu area
med-tech reimburs believ warrant monitor
foreign exchang rate roughli half sale coverag univers deriv
outsid unit state thu foreign exchang rate fluctuat impact sale
profit figur illustr sale distribut across coverag univers
strengthen us dollar impact sale profit med-tech
compani past expect headwind look ahead next
four quarter believ could bring earn risk across coverag univers
near-term earn risk near-term ep estim across coverag univers
gener thomson reuter consensu estim attribut
factor recent foreign exchang rate movement well slightli higher tax rate
benefit expect repeat believ temper sale
earn outlook near-term risk group
quarterli annual ep usd
consensu number thomson reuter receiv gmt
diversifi growth new product tailwind initi
initi coverag abbott laboratori overweight rate price
target posit invest stanc turn follow
favor mix busi past five year abbott manag
intent alter compani mix busi weight toward
faster growth higher-margin busi specif abbott divest slower
growth develop market establish pharmaceut busi acquir st jude
medic today abbott sale attract weight medic devic
nutrit diagnost emerg market establish pharmaceut
abbott sale also attract diversifi geograph perspect
sale unit state sale emerg market
new product cycl sustain above-averag sale growth abbott sale growth rate
acceler past year above-industri growth rate see sever
new product sustain momentum key new product includ
abbott freestyl libr blood glucos monitor devic alin seri diagnost
system abbott host pipelin product well particularli area
double-digit ep growth sustain look ahead continu expect abbott
net incom ep growth outpac sale growth abbott plan continu
pay debt turn drive financi leverag also expect abbott
deliv oper margin expans combin busi mix
merger synergi well cost reduct program believ abbott sustain
constant currenc ep growth low-doubl digit next three five year
valuat risk
set price target primarili reli forward price-to-earnings methodolog
price target appli multipl ep estim believ
multipl least sustain given above-p growth prospect
risk relat achiev earn estim price target object
market competit product launch regulatori action chang reimburs
price pe histori
compani sale product group
compani sale geographi
abbott evolv portfolio favor mix
leadership ceo mile white abbott laboratori transform
past two decad fairli constant portfolio manag abbott
diversifi healthcar compani posit basic medic suppli well
brand pharmaceut notabl portfolio move includ spin-off
hospit suppli busi hospira acquisit guidant vascular asset
spin-off brand pharmaceut busi sale
develop market establish pharmaceut busi divestitur
medic optic acquisit st jude medic aler
today abbott sale attract view weight medic devic
nutrit diagnost establish pharmaceut abbott
geograph sale mix also attract diversifi sale unit
state sale emerg market believ abbott product geograph
mix sustain sale growth least mid-singl digit long term
sale product categori
sale product categori
medic devic leader cardiovascular
abbott medic devic divis includ broad array devic includ rhythm
manag electrophysiolog heart failur vascular structur heart diabet
devic cardiovascular neuromodul product gener sold hospit
ambulatori surgeri center physician offic diabet devic sold consum
mail order pharmaci independ retail
nutrit leader infant formula
abbott nutrit divis includ pediatr adult nutrit product
brand market abbott includ similac infant formula isomil infant formula
perfect bar adult nutrit myoplex adult nutrit advantedg adult nutrit
product gener sold consum well institut wholesal
retail healthcar facil govern agenc
diagnost leader immunodiagnost
system point care system rapid diagnost system product gener
sold blood bank hospit commerci lab clinic physician offic govern
agenc altern care test site plasma protein therapeut compani
establish brand gener emerg market
abbott establish pharmaceut divis epd market extens portfolio
brand gener pharmaceut emerg market focu key market
india russia china brazil abbott five broad therapeut area focu
gastroenterolog product women health product cardiovascular metabol
product pain central nervou system product respiratori drug
vaccin brand gener drug gener sold directli wholesal distributor
govern agenc health care facil pharmaci independ retail
see multipl new product sustain above-averag sale growth
abbott organ sale reflect epd growth
diagnost sale growth nutrit sale growth estim medic
devic ex-st jude growth abbott expect organ sale growth
estim increment revenu freestyl libr account
nearli growth
abbott sale organ growth rate post spin
look ahead believ could moder sale growth rate
current level legaci aler busi rapid diagnost becom part
organ base post acquisit anniversari still see growth solidli mid-
singl digit would anticip abbott medic devic busi grow mid-to-
high singl digit given underli trend market coupl sever new
product roll-out expect diagnost divis continu grow mid-singl
digit abbott benefit global launch alin system nutrit
expect sale grow low-to-mid singl digitsconsist overal market
growth rate lastli believ establish pharmaceut busi could grow
mid-to-high singl digit reflect overal market growth rate coupl solid
execut launch new product
follow number product recent launch expect
launch come year underpin growth assumpt divis
freestyl libr continu glucos monitor system includ handheld
reader dispos sensor worn back upper arm abbott first
launch freestyl libr system europ sensor system
approv us fda septemb latest gener sensor
approv us fda juli worn day octob
real-tim alarm function previous competit disadvantag
rel cgm system market abbott also evalu use pediatr
patient product current approv adult year older
freestyl libr system use peopl diabet global
countri last year sale total around million year
could around billion view freestyl libr potenti multi-
billion dollar product abbott next sever year compani continu
grow intern proce roll-out unit state
alin diagnost system integr famili next-gener diagnost
system solut intern market abbott roll alin
clinic chemistri alin immunoassay diagnost alin blood
plasma screen late abbott receiv fda approv alin
alin system await approv critic mass assay
execut fulli roll-out plan alin molecular diagnost approv
use europ expect approv us late collect
believ system launch sustain improv upon abbott mid-single-
transcathet mitral valv repair abbott mitraclip current fda approv
transcathet mitral valv system mitraclip system use treat patient
signific symptomat degen mitral regurgit mr determin
prohibit risk mitral valv surgeri mitraclip deliv via cathet
heart oppos tradit open-heart surgic method mitraclip approv
europ sinc march avail unit state sinc octob
juli abbott receiv fda approv next-gener mitraclip system
includ advanc steer navig posit capabl clip
addit clip size also design mitraclip use patient
world-wide abbott coapt trial result recent present tct confer
coapt evalu use mitraclip system patient diagnos grade
moderate-to-sever grade sever secondari function mitral regurgit
mr heart failur ischem nonischem cardiomyopathi left ventricular
eject fraction patient also deem least high surgic
risk studi particip requir least one hospit heart
failur prior month adequ treat per applic standard
includ studi result show patient receiv mitraclip therapi
significantli lower rate hospit heart failur all-caus mortal
within month follow-up compar medic therapi alon abbott estim
address us patient popul today patient coapt
potenti doubl tripl address number patient would valu
opportun excess billion world-wide sale total around million
pace around million year
transcathet mitral valv replac abbott acquir tendyn mitral valv
replac system august devic evalu treatment
symptomat sever mitral regurgit ce mark trial enrol complet
abbott expect launch system earli europ respect unit
state market juli abbott receiv fda approv begin pivot
summit trial evalu tendyn mitral valv patient mitral
regurgit patient studi random ratio tendyn devic
convent mitral valv surgeri primari endpoint composit endpoint
death cardiovascular hospit stroke reoper one year would
anticip trial could take two year enrol put data read-out late
approv possibl
transcathet aortic valv also area develop abbott abbott
transcathet aortic valv program acquir vis-a-vi acquisit st jude
medic portico valv receiv ce mark european approv
current clinic trial phase unit state data portico studi
present tct confer show favor clinic outcom
safeti perform data us pivot trial expect releas
american colleg cardiolog confer march data
pivot studi posit fda approv launch possibl late
would allow abbott gain share total transcathet aortic valv
market estim approach billion sale
transcathet tricuspid valv august abbott initi enrol
trilumin ce mark trial clip-bas transcathet tricuspid repair system
build mitraclip system studi evalu symptomat patient
unit state europ primari endpoint
echocardiograph tricuspid regurgit reduct grade day
procedur assess major advers event month abbott expect
complet trial late ce mark european approv late us
pivot trial expect begin abbott estim roughli million
undertr patient eu us
left atrial appendag occlud left atrial appendag laa small pouch
wall left atrium blood collect laa form danger clot
caus stroke particularli concern patient atrial fibril
abbott obtain laa technolog st jude medic acquisit
acquir technolog aga medic acquisit first gener
devic known amplatz cardiac receiv ce mark
next-gener devic amplatz amulet laa occlud receiv european ce
mark approv januari us clinic trial amplatz amulet
initi septemb trial random patient either amplatz
amulet devic boston scientif watchman laa closur devic control
group enrol expect complet earli follow-up
complet sometim late would put potenti fda approv
second half estim left atrial appendag market roughli
million size today potenti grow billion given number
patient atrial fibril
heartmat august abbott receiv fda approv full maglev
left ventricular assist system lvad manag advanc heart
failur patient need short-term hemodynam support bridge-to-transpl
bridg myocardi recoveri march long-term trial result
releas american colleg cardiolog confer long-term
cohort met primari endpoint event free surviv surviv free disabl
stroke devic remov due malfunct show superior heartmat ii
lvad result also show improv surviv low pump thrombosi lower
stroke rate compar heartmat ii lvad abbott submit result fda
support long-term destin therapi indic heartmat lvad
anticip approv end year
percutan heart php abbott acquir percutan heart php
program st jude medic acquisit st jude acquisit thoratec
heartmat php percutan heart pump design deliv blood
flow mean flow stabil hemodynam compromis patient
heartmat php devic receiv ce mark european approv juli
support patient undergo high-risk percutan coronari intervent pci
shield ii us pivot trial initi howev abbott identifi small
number clinic event associ pump stoppag support high risk
pci patient clinic commerci use prompt abbott halt
studi european sale abbott evalu design modif
still pursu develop devic though timelin indic
market hemodynam support product measur billion abiom
impella lead product sale nearli million
drug-coat balloon februari abbott announc sign
agreement wherebi abbott obtain exclus world-wide
commerci right surveil drug-coat balloon surveil current
studi transcend pivot trial enrol trial
random patient receiv either surveil dcb pact admir dcb
primari efficaci endpoint trial primari patenc defin composit
freedom restenosi clinically-driven target lesion revascular tlr
month post-index procedur expect trial enrol run next
summer/fal would put result read-out late potenti approv
addit surveil dcb abbott also receiv option negoti agreement
below-the-kne arterioven av fistula drug-coat balloon
product estim drug-coat balloon market million market
categori capabl expand billion
see path sustain double-digit constant currenc ep growth
sinc spin-off abbott oper margin expans function
improv certain oper divis notabl diagnost well busi mix
 increas weight medic devic combin top line well touch
financi leverag vis-a-vi stock repurchas abbott consist grown
ep rate double-digit pace constant currenc basi
ep ep growth
abbott expect organ sale growth estim increment
revenu freestyl libr account nearli growth manag expect
diagnost contribut sale littl billion year oper
margin flattish due reclassif pension incom non-oper
incom target invest spend around million reinvest
upsid us tax reform slight dilut impact aler abbott expect
ep rang reflect growth mid-point
look ahead believ addit oper margin expans possibl result
favor busi mix well achiev remain cost synergi st
jude medic aler acquisit also view financi de-lever sourc
ep growth consumm billion st jude medic billion aler
acquisit abbott lab issu consider amount debt year-end abbott
total debt stood billion sinc abbott paid total
billion debt goal reach net debt ebitda end year
net/net expect ep growth moder slightli mid-teen level remain
doubl digit
illustr figur revenu project slightli street
attribut potenti greater expect headwind currenc illustr figur
essenti line street year slightli street
thereaft expect fx headwind earn next year also believ abbott
may manag ep growth closer ep growth level therebi reinvest
upsid
chang ex-fxepsep adjustedy/i chang ep adjusteddoubl digit ep growth ex-fx barclay medic suppli devic
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight view abbott high-qual
growth asset believ compani
favor mix busi product
geograph perspect see medic devic
busi key driver growth go forward
believ growth profil warrant premium
upsid case depend sever key factor
approv new product greater traction new
product success integr st jude
aler busi stable-to-improv trend
downsid case driven foreign
exchang rate slowdown emerg market
growth inabl receiv product approv
quarterli annual ep usd
consensu number thomson reuter receiv gmt
chart new better cours ip sale initi
equal weight
initi coverag avano medic equal weight rate price
target neutral invest stanc turn follow
 ip divestitur provid rebirth compani divestitur surgic
 infect prevent ip asset avano lost halyard brand also
albatross around compani growth perspect see sale
posit catalyst chang believ manag team right strategi
redeploy ip proce medic devic growth initi
think stock risk/reward seem fairli evenli balanc current level
share year-to-d octob attribut
market enthusiasm around ip sale prospect better time ahead
believ street fairli model long-term outlook could
near-term earn risk compani seek invest growth initi
believ avano stori like turn futur avano plan use
proce ip sale fund futur acquisit think wise
strategi enhanc compani exposur better end market said
there still risk valuat ultim paid asset compani
abil success execut deal
valuat risk
set price target use combin enterpris value/sal
forward price-to-earnings methodolog share current trade
sale estim increas confid abil sustain/rais sale growth
compani believ multipl could expand closer use
estim would impli valuat per share avnss current ep depress
compani recent sold ip busi compani incur strand cost
associ expect ep base normal believ anv like trade
premium med-tech group earn growth rate higher appli
multipl ep estim discount back rate arriv
impli valuat weight approach result price target
risk relat achiev earn estim price target object
includ futur deploy cash relat acquisit abil success
product launch regulatori action chang reimburs
price pe histori
compani sale geographi
compani sale product group estimate
chronic barclay medic suppli devic
formerli halyard health product strategi shift spin-off
divestitur halyard health form spin-off corpor
healthcar busi octob healthcar franchis
found late consist primarili surgic infect prevent product
 surgic gown drape glove respiratori product strategi busi
unit invest higher-growth higher-margin medic devic market end
acquir bayli medic compani pain manag busi
exclus us distributor brought compani
coolief technolog also acquir i-flow on-q drug
spin-off halyard strategi stand-alone compani remain
focus shift mix toward higher growth margin medic devic busi
time spin medic devic busi repres one-third oper
profit repres two-third meanwhil surgic infect prevent
 ip segment consist struggl price eros input cost volatil
offset much growth come medic devic segment
novemb halyard announc sale ip busi owen minor
deal close april effect june halyard health chang name
inc sold name halyard health owen minor
follow sale ip busi avano sole focus medic devic
focu pain manag chronic care busi gener
million revenu expect grow organ basi
product primarili sold unit state
compani sale product group estimate
compani sale geographi
chronic barclay medic suppli devic
proce ip sale provid addit capac
halyard health sold ip busi along name halyard health owen
minor total purchas price million
sale ip owen minor provid avano gross proce million
net proce approxim million halyard use proce
million retir remain portion senior secur loan manag intend
invest remain proce back busi acquisit organ
growth follow close deal june avano million
cash restrict cash million debt
manag estim follow ip divestitur million
acquisit capac moreov manag comment focu acquisit
leverag exist technolog expand call point increas address
first deploy capit juli acquisit coolsystem inc
market game readi game readi total consider million game
readi revenu approxim million result price sale
valuat nearli revenu game readi market-lead provid cold
therapi compress therapi system market primarili orthopaed sport
injury-rel end market avano intend leverag game readi strong orthopaed
surgeon relationship continu
orthopaed
procedur manag note game readi current grow slightli faster
avano manag expect deal immateri adjust ep slightli
accret earn
manag comment game readi perfect exampl approach
 insofar complementari acquisit expand portfolio well
sale channel call point expect manag continu look corpak
game readi type deal though would necessarili rule larger deal could
transform manag also comment transform deal
could million size deal
estim avano pain manag franchis gener sale million
total sale segment includ non-opioid intervent coolief
acut on-q pain
intervent pain busi focus minim invas pain relief patient
suffer chronic pain throughout spine larg joint avano compet
radiofrequ rf ablat segment coolief rf ablat technolog rf
proven provid pain relief far month current almost entir
use treat chronic spine pain knee pain hip pain compris
procedur volum respect avanoss coolief market share leader
estim sale grown compound-annual-growth-rate
radiofrequ ablat treatment chronic pain
us rf procedur anatomi
tradit rf ablat minim invas procedur use thermal energi heat
destroy nerv fiber stop transmiss pain signal brain coolief
differenti standard rf treatment use water-cool technolog instead
heat gener energi use heat limit amount rf energi abl
deliv given time therebi limit effect standard rf treatment
shape lesion use thermal energi also ellipt necessit probe
place parallel target nerv order success ablat nerv fiber
use cool rf technolog allow addit rf energi creat lesion
volum thermal rf lesion shape spheric allow physician
approach target nerv perpendicularli well parallel combin allow
use permiss
new oa indic pend code
coolief receiv fda approv manag chronic osteoarthr oa knee
pain april coolief remain rf ablat treatment approv
treatment chronic moder sever knee pain caus osteoarthr indic
expans knee pain provid increment million patient popul
coolief reimburs profil today larg hospit expect
institut separ code cover new procedur rf nerv ablat januari
either acut ambulatori surgic center offic set chronic pain due
oa knee level reimburs associ code remain
uncertain improv reimburs environ could lead meaning uptak
procedur treat osteoarthr relat knee pain note code would
cover rf nerv ablat would expect avano increas market regard
coolief label differenti technolog ahead
avano continu invest build clinic evid order show coolief
effect current treatment chronic knee pain septemb compani
announc studi result show month coolief provid
significantli greater longer-last pain relief improv physic function higher
patient satisfact corticosteroid inject
pain reduc least month
report wors pain month
report pain month
oxford knee score month
improv global perceiv effect
region anesthesia pain medicin januari
avano current recruit studi compar efficaci coolief vs hyaluron
acid ha intend initi studi versu tradit rf ablat well studi vs
ha expect enrol patient evalu proport subject
greater equal pain reduct six month measur advers
event month accord clinicaltri gov studi expect complet data
collect primari outcom measur april data favor
acut pain busi focus treatment surgic pain without use
opioid danger opioid use highli public recent year lead
increas focu fda organ meaning reduc opioid
prescript along increas cost associ even properli use
opioid treatment extend length stay therapi complic act constant
driver share gain non-opioid altern
avano on-q pain relief ambulatori pain pump provid pain relief
five day on-q balloon type pump fill local anesthet
deliv cathet place near surgic site physician pump
program infus local anesthet steadi rate model allow
patient control dose level
avano estim address market greater million procedur annual
greater billion avano call varieti procedur on-q
sale relat orthoped procedur manag recent note shift
sale market focu emphas orthoped ob-gyn procedur
market opportun specialti billion total
year on-q pump sale neg impact two factor first nation
bupivacain shortag pain medicin predominantli use on-q pump began
bupivacain shortag like remain headwind throughout second
key third-parti unabl fill pump due find fda audit order
off-set impact loss third-parti pump filler approxim account
avano ad leiter enterpris outsourc provid altern sourc
custom purchas on-q pump facilit hospit ad third-
parti supplier purchas protocol manag believ posit impact
sourc maneuv begin show impact
estim on-q grow least mid-singl digit normal market condit
on-q trac on-line patient engag platform help physician hospit
monitor measur track patient post-op satisfact improv overal patient
experi patient enrol platform surgeri invit provid
inform variou time intervalsfrom pre-op post-surgeri
physician proactiv interven adjust patient care improv outcom
ezstim peripher nerv locat stimul
ezstim help clinician monitor effect muscl relax drug gener
anesthesia enhanc effect cathet placement continu
peripher nerv block cpnb acut pain use cpnb help improv
patient care mitig need opioid post-op pain manag
ezstim hand-held devic serv either full-funct nerv locat
chronic franchis respiratori digest health
avano oper chronic busi two sub-seg respiratori
digest estim chronic busi gener million revenu
look ahead believ could grow mid-to-high singl digit
intermedi term intern growth potenti long-term opportun
respiratori health busi focus support patient ventil
specif reduc occurr ventilator-associ pneumonia vap vap
link hospital-associ pneumonia case cost averag
elimin format channel typic found pvc cuff reduc leakag
ballard close suction system featur technolog ballard trach care
cathet retract within isol vacuum-s turbul clean
chamber result cleaner cathet tip compar standard close
oral solut icu ventil assist pneumonia risk
increas increas dental plaqu oral care kit offer complet portfolio
improv complianc oral care standard care icu
avano digest health busi focus enter feed market enter feed
requir patient function gastrointestin gi tract swallow
digest food normal lead malnutrit malnutrit caus mani
medic condit becom intermedi long-term condit estim
digest health busi grow mid-to-high single-digit rang base
busi grow mid singl digit corpak busi grow high singl
cortrak enter access ea acquir may part
corpak acquisit cortrak fda-clear devic abl confirm bedsid
tube placement without x-ray cortrak system use short-term feed
mic-key feed tube typic use day mic-key enter
feed tube low-profil devic sit skin level avano maintain share
low profil balloon gastrostomi tube market
readi limit impact foreign exchang manag expect tax
rate rang adjust dilut ep rang
includ earn divest ip busi
avano laid long-rang plan investor day june plan
illustr figur forecast acceler top-lin growth mid-singl
high-singl digit along improv profit
embed within assumpt improv margin avano cost transform
program avano estim left approxim million dis-
synergi follow ip divestitur repres cost previous alloc across
 ip medic devic segment cost sole alloc
remain medic devic busi avano intend off-set strand
cost million annual save see figur save
expect come gener organ right size improv inform technolog
optim distribut network suppli chain procur save well
continu program zero-bas budget lean manufactur
mm
take outlook
full-year consensu current estim report revenu growth
approxim adjust ep continu oper
view reason line expect year
look howev believ street could mis-model like increas
sg spend caus ep overst manag note would
meaning acceler sg spend due continu fund growth
invest strateg prioriti
pain
manag franchis believ like continu
modestli off-set forecast cost save believ sg percent
revenu like declin slower rate street expect due increas
spend shown figur ep estim street versu
respect howev look ahead beyond believ avano
see step-up margin greater cost save kick ep estim
fairli in-lin street
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight view sale ip
posit catalyst believ compani
right strategi redeploy ip proce
medic devic growth initi stock
signific upsid believ current price
larg captur success reach long-rang
goal outlin june analyst day
upsid case could driven greater sale
growth greater margin expans
success lead improv outlook
downsid case could driven deceler
sale growth trend inabl achiev cost
save unsuccess
quarterli annual ep usd
consensu number thomson reuter receiv gmt
long-term outlook near-term ep risk initi
underweight
initi coverag baxter intern underweight rate price
target invest stanc turn follow
signific stride made sinc baxalta spin-off sinc spin-off
bioscienc baxalta appoint almeida ceo
januari baxter significantli improv margin cash flow
signific stride still come baxter expect sale growth acceler
long-rang plan lrp averag compound-annual-growth-rate
baxter expect oper margin expand
turn lead robust ep growth lrp period
howev think market high expect see risk ahead
past two year baxter consist beat-and-rais stori believ
market expect beyond may high baxter rais
guidanc throughout year consequ street model higher
expect beyond howev believ factor benefit
like repeat gener competit cyclo brevibloc fda
warn letter relat clari fx higher tax rate could headwind near
term ep estim thomson consensu estim
ep estim also thomson consensu
estim line baxter long-rang plan target
issu may
valuat risk
set price target primarili reli forward price-to-earnings methodolog
price target appli target pe ep estim
med-tech sector trade averag premium market sinc
believ share trade premium averag reflect higher earn
risk relat achiev earn estim price target object
includ time pace gener competit new product approv uptak new
chang reimburs
price pe histori
compani sale product group
compani sale geographi
signific stride made post baxalta spin-off
baxter histori includ period success well challeng compani
undergon fairli signific portfolio manag year includ sever notabl
spin-offscaremark mail order pharmaci allegi corpor medic
suppli distribut edward lifesci cardiovascular baxalta
bioscienc unit
spin-off baxalta juli result remainco baxter narrow focu
hospit suppli select pharmaceut renal product januari baxter
board director appoint industri veteran almeida posit ceo almeida
previous ceo covidien acquir januari
almeida leadership baxter made substanti progress across number
financi metric display figur thu far compani continu
improv margin cash flow metric
baxter look pois continu improv growth profit
baxter recent provid updat long-rang plan analyst day
may baxter expect sale growth acceler lrp period sale
averag acceler period
contribut new product geograph expans new product
expect account growth long-rang plan key new
product includ follow
million baxter plan introduc new molecul
lrp expect equat new product new
registr baxter specif molecul expect bring market
say area anesthesia anti-infect cardiovascular
oncolog specialti care baxter built pharmaceut presenc
last year acquisit clari expand gener inject portfolio
partnership scinopharm includ gener inject
use cancer treatment option add molecul
renal million baxter plan number new product area renal
therapi lrp signific launch includ kaguya theranova
us china point system launch kaguya autom
periton dialysi system design japanes market underway
sinc march baxter believ system help expand use pd
japanes market baxter also plan launch theranova dialyz
unit state along hemodialysi system latter
use deliv expand hemodialysi hdx enabl theranova
dialyz baxter also plan launch point system would allow
concentr pd solut significantli reduc amount need
medic deliveri million main new product baxter area
medic deliveri includ latest iter spectrum pumpspectrum iq
well new pump platform also includ syring pump market baxter
particip today baxter also continu launch evo iq
infus pump intern market plan launch evo iq syring
baxter also intend enter new market special monitor
acut therapi million key new product acut therapi busi
prismax system baxter next gener extracorpor blood purif also
refer continu renal replac therapi crrt system
launch select countri year see continu global expans
come year prismax offer varieti improv prior gener
prismaflex includ sever new function enhanc color touch screen
option autodrain tube remov need wast bag reduc prime
time longer filter life span reduc blood pump stop reduc bag time chang
improv alarm
macronutri micronutri autom compound system new
product launch includ oliclinomel chines market olimel
finomel emea region well clinimix hp unit state
advanc surgeri million baxter number new product pipelin
advanc surgeri busi includ tisseel prima syring neurotub
coupler remot monitor arteri coupl floseal prep floseal ready-to-us
baxter expect see continu oper margin expans driven cost
reduct importantli product mix specif baxter expect oper
margin reach expand adjust ep
expect expand oper cash flow free cash flow
expect increas billion billion respect summari
lrp illustr figur
believ market high expect baxter perhap high
baxter consist rais annual guidanc past three year
past three year baxter manag consist rais ep outlook
primarili base success cost cut margin expans higher-than-
expect contribut cyclophosphamid oncolog drug also aid
financi outlook/perform figur illustr baxter initi fiscal year guidanc
along actual perform baxter ep
initi guidanc mid-point baxter ep initi
guidanc mid-point also show initi guidanc along current
guidanc reflect higher expect year year current mid-
point higher initi guidanc mid-point
ep rel guidanc mid-pt
oper sale growth exclud effect foreign exchang gener cyclophosphamid strateg exit acquisit
upwardli revis outlook sever time
conjunct spin-off baxalta baxter held analyst meet may
discuss long-term outlook remainco baxter meet baxter manag
outlin lrp target includ target year sinc baxter
repeatedli updat view outlook shown figur
outlook
believ upward revis lead expect continu beat
believ import keep reason behind higher earn revis
would attribut beat better oper perform
predominantli area better-than-expect cost manag cyclophosphamid
proven favor baxter number impact gener entrant
proven difficult forecast estim increment earn associ
favor contribut rel initi plan ad per share
ep respect
far year baxter rais ep guidanc mid-point
math higher cyclophosphamid profit contribut higher brevibloc iv
beta-block sale due competitor suppli issu contribut also lower
tax rate due greater benefit stock compens guidanc well
discret item ad leav oper factor
current thomson consensu ep estim high end
guidanc rang believ seem achiev estim also
beatabl extent gener competit cyclo brevibloc less expect
concern market financi expect
barclay versu street see headwind baxter
cyclophosphamid brevilock gener eros baxter gener
competit cyclophosphamid sinc novarti sandoz unit receiv approv
novemb howev competit pressur great limit
entrant receiv fda approv cyclophosphamid march
though expect impact late baxter
brevibloc benefit competitor issu baxter may see eros
breviloc sale face gener version approv
septemb estim cyclophosphamid brevibloc sale like
total around million sale could reduc half next year
repres impact sale growth estim repres nearli
headwind ep
clari warn letter juli clari receiv warn letter fda
prevent baxter market new approv clari us
warn letter lift manag expect facil abl launch new
product us begin estim reduc number new
launch expect time acquisit
tax rate comparison baxter tax rate expect around
compani benefit among thing excess benefit stock
compens expect normal tax rate baxter guidanc
normal rate respect
model compar delta per share
foreign exchang rate baxter gener nearli sale outsid unit state
emerg market repres sale compani financi
well natur hedg vis-a-vi divers manufactur footprint currenc could
headwind next year
barclay versu street thomson consensu estim
ep updat long-rang plan outlook issu may
appear us market assum higher ep guidanc rais
juli translat higher level and/or compani continu
beat-and-rais stori project ep
believ long-rang plan goal achiev primarili predic
success new drug launch pharmaceut isnt lot visibl
underweight believ baxter pois
drive sale growth acceler new
product launch howev believ
consensu expect high see
earn risk competit gener launch
inabl launch pharma product due
warn letter higher tax rate fx ep
estim street
upsid case could driven gener
competit less expect greater
success bring new product market
greater-than-expect improv profit
downsid case could driven greater-
than-expect cyclo brevibloc sale
competit pressur renal medic
deliveri foreign exchang rate
strengthen us dollar
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
co quarterli annual ep usd
consensu number thomson reuter receiv gmt
equal weight
initi coverag becton dickinson equal weight rate price
target invest stanc turn follow
posit fundament outlook addit bard believ becton
dickinson posit consist top-lin growth compani
also see opportun margin expans realiz cost synergi
relat bard acquisit on-going cost optim effort product mix
top line growth prospect margin expans potenti financi leverag
compani pay debt allow becton dickinson sustain adjust
ep growth doubl digit
carefus integr went well leav market high hope bard
becton acquir carefus integr went well bard
rais amount deal cost synergi believ market expect becton
likewis rais cost synergi target bard though dont believ
materi near term
street forecast fiscal may high releas
fiscal result novemb like issu fiscal guidanc
believ may risk consensu forecast given recent foreign
exchang rate particularli strengthen us dollar rel emerg market
currenc raw materi cost dilut associ
advanc
bioprocess divestitur project ep versu street
valuat risk
set price target primarili reli forward price-to-earnings methodolog
price target appli target pe calendar ep estim
sinc share trade premium market believ
premium line med-tech sector histor averag appropri
given improv underli growth compani
risk relat achiev earn estim price target object
includ success integr bard achiev revenue/cost synergi
launch regulatori action dilut associ chang reimburs
price pe histori
compani sale product group pro forma
compani sale geographi pro forma
becton transform portfolio recent year acquisit
transform portfolio past five year becom larger
divers compani march becton dickinson complet billion
acquisit carefus ad infus pump medic manag
medic suppli portfolio decemb complet
billion acquisit bard ad peripher intervent surgic access
urolog product mix
bd sale product categori
bd sale product categori pf
carefus well-integr sharehold value-ad deal
track record med-tech acquisit mix carefus acquisit
stand us deal success integr ad valu
sharehold judg rel out-performance stock follow deal
stock perform post deal announc date rel market
becton dickinson acquir carefus march billion cash stock
rational acquisit build scale depth medic manag
time transact becton dickinson expect transact provid
double-digit cash ep accret bd first full year becton also initi identifi
million pre-tax cost synergi fulli realiz fiscal year integr
proceed smoothli becton dickinson rais ep accret target well
increas cost synergi target million integr larg complet
bd achiev upwardli revis cost synergi target
bd portfolio evolut continu bard acquisit
decemb acquir bard billion cash stock
becton state strateg rational deal includ acceler end-to-end medic
manag infect prevent creat new opportun across rang
clinic impact segment leverag bd global capabl creat new
opportun benefit combin compani product portfolio
compani report note gore royalti revenu exclud vascular sale
time deal announc april becton expect gener low-
single-digit accret adjust ep fiscal high-single-digit accret
adjust ep fiscal also expect gener pre-tax annual cost synergi
million fiscal
becton dickinson nine month integr bard believ
integr go smoothli legaci bard busi sustain sale
momentum underli growth adjust hurrican impact
underli growth
lutonix increas competit reimburs headwind
bard acquisit becton dickinson acquir lutonix percutan
translumin angioplasti pta drug coat balloon dcb bard began sell lutonix
us octob devic ad overal compani growth
throughout first year pact admir dcb receiv approv shortli
thereaft decemb lutonix pact admir larg split us dcb market
juli philip receiv fda approv stellarex dcb addit competit
like come us market expect bring ranger dcb
us market abbott/surmod like launch
bard becton dickinson work enter new geographi expand
product indic lutonix receiv fda approv use end stage renal diseas
esrd patient stenot lesion dialysi arterioven av fistula august
expect pma submiss below-the-kne btk trial
regard reimburs transit pass-through payment dcb expir
decemb categor dcb devic bill code plain
balloon angioplasti becton dickinson manag note expect see
minim impact reimburs chang expect growth line
histor dcb growth rate larg due av access indic expans view
take financi outlook
shown figur bd histor revenu fiscal period averag
annual growth addit bard believ becton dickinson
posit consist higher top-lin growth compani expect
margin expans realiz cost synergi relat bard acquisit
on-going cost optim effort product mix top-lin growth along margin
expans financi leverag compani pay debt allow becton
dickinson sustain adjust ep growth doubl digit
note adjust flu pandem comp compar basi
adjust dispens hurrican impact
look ahead benefit high-single-digit accret associ
bard acquisit howev believ could risk earn
outlook thomson consensu ep estim may high pro
con next year includ
foreign exchang becton dickinson gener roughli sale us
europ remaind rest world emerg market
repres approxim sale base current foreign exchang rate
estim headwind fiscal could excess sale percent
drop-through top line vari illustr figur use drop-
assumpt estim fx could headwind per share
fx impact revenu profit ep million except per share figur
prior year
revenue drop-thru
prior year
raw materi cost becton identifi fluctuat cost avail oil-
base resin raw materi risk becton spend million year
resin fiscal resin cost increas pressur earn
becton state believ could see similar impact fiscal
tariff becton dickinson estim could see impact
chines tariff fiscal
divestitur advanc bioprocess
announc reach agreement sell advanc bioprocess
busi bd manag comment unit annual sale
million earn contribut fiscal would around per
share thermo fisher disclos purchas price million expect net
proce use pay debt net/net howev expect dilut
sale busi deal expect close earli assum close
end would impli potenti dilut around per share ep
pension expens believ pension expens could slightli favor next year
higher discount rate due rise interest rate would slightli reduc pension expens
consensu estim fiscal impli ep growth
believ consensu estim may bit high adequ reflect
impact foreign exchang also concern outlook given
gore royalti ceas late august royalti trend higher
gore royalti end august
bard began receiv royalti gore associ gore case
date back gore found wil infring bard patent
relat vascular graft stent-graft compani record gain million
million tax includ compensatori damag enhanc damag
past royalti award began collect royalti rate
certain gore vascular product begin life patent
gore royalti allow bard invest heavili sg
expect end august potenti potenti earn disrupt
on-going question investor estim gore royalti incom
report incom expens current annual north million
estim per share basi gore royalti approxim fiscal
ep becton dickinson manag believ abl mitig
impact earn pay debt therebi reduc interest expens realiz
addit revenu cost synergi bard acquisit
co
equal weight believ bd continu
success integr bard achiev plan
synergi though market alreadi appreci
base success integr carefus think
street forecast may high given current
foreign exchang rate commod cost
current believ stock like
upsid case could driven better-than-
bard acquisit improv overal
growth rate higher earn
downsid case could driven foreign
exchang rate stronger us dollar could
slower-than-expect sale legaci bard
busi slowdown emerg market
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
quarterli annual ep usd
consensu number thomson reuter receiv gmt
consensu long reason initi overweight
initi coverag boston scientif overweight rate price target
invest stanc turn follow
robust pipelin across three busi unit number new
product continu drive averag sale growth next sever
year notabl new er product includ watchman left atrial
urolog product believ investor gain appreci depth
pipelin compani investor day next year sale forecast ahead
street next two year
oper margin expans continu moder oper
margin goal slightli accommod invest spend dilut
associ acquisit howev manag still expect see
oper margin expans next sever year given robust top line
margin expans believ double-digit ep growth like
valuat risk
set price target primarili reli forward price-to-earnings methodolog
believ premium valuat warrant given believ sustain
averag growth profil current trade ep estim given strong
top line growth prospect believ multipl expand price target
appli pe multipl ep estim sinc boston
scientif trade wide rangea rel premium discount
averag premium market believ premium histor averag
warrant given improv underli fundament
risk relat achiev earn estim price target object
includ new product approv uptak new product risk factor includ
regulatori action market share loss stent dilut acquisit greater
expect product liabil chang reimburs
price pe histori
compani sale product group
compani sale geographi
turnaround impress
histori one great success success launch taxu
drug-elut stent challeng guidant acquisit stock histori
reflect period all-tim high stock achiev april
month taxu launch all-tim low stock
juli j-guidant lawsuit sinc all-tim low share climb
back high compani execut turnaround plan
acceler underli sale growth expand oper margin organ
sale perform improv sale declin recent
increas respect track
organ sale growth year
acquisit aid underli improv
found acquisit alway play central role
growth strategi made sever strateg
therapeut schneider continu
make target acquisit well strateg invest acquisit includ cardiac
pathway advanc bionic corpor notabl guidant
guidant largest transact far purchas price net cash acquir
divestitur intevent busi abbott billion
follow guidant acquisit paus serial acquisit strategi
took debt fund transact focus integr activ free cash
flow perform impact numer special charg fact compani
revert divestitur strategi rais cash pay debt well fund smaller
strateg acquisit boston scientif complet sale non-strateg
busi gross proce billion includ sale auditori cardiac
surgeri vascular surgeri fluid manag venou access endovascular aortic
repair busi boston scientif close sale neurovascular
busi purchas price billion
proce asset sale along improv free cash flow gener
allow revert back serial acquir acquisit smaller
scale tuck-in mainli focus ad technolog leverag exist
portfolio acquisit acquir key new product includ
asthmatx asthma treatment atritech watchman sadra medic lotu
cameron health subcutan symeti acur apama
medic ep nxthera rezum acquisit expand boston
scientif exist franchis includ rhythmia medic electrophysiolog bard
electrophysiolog unit ep bayer intervent busi american
urolog endochoic gastroenterolog
boston scientif particularli activ year total eight
acquisit one invest option acquir
boston scientif invest acquisit
invest option buy
thermal monitor system continu
measur esophag temperatur
women health devic diagnosi ovarian
rezum system minim invas treatment
venou stent treat venou obstruct
spaceoar system therapi reduc side effect
new product maintain peer sale growth
view pois grow top line peer rate driven
continu roll-out sever key product along potenti revenu host
new product launch next sever year key exist
watchman left atrial appendag closur devic left atrial appendag laa
small pouch wall left atrium blood collect laa form
danger clot caus stroke particularli concern patient
atrial fibril watchman receiv ce mark though
commerci boston scientif acquir technolog may
watchman receiv fda approv march devic current indic
treatment altern patient atrial fibril either indic contraind
anticoagul therapi target eu launch watchman
flx devic us trial current underway approv like
period sale watchman approxim million given
number patient suffer atrial fibril market opportun
product could exceed billion see competit year
ahead abbott aim launch amplatz amulet devic late
lotu transcathet aortic valv boston scientif two shot goal
come enter billion transcathet aortic valv market lotu valv
receiv ce mark european approv octob octob boston
scientif suspend launch initi voluntari remov field inventori due
report devic could fulli lock procedur due
prematur releas pin connect lotu valv deliveri system februari
boston scientif initi remov lotu valv devic global
commerci clinic site due aforement issu boston scientif
address technic issu product plan re-launch lotu
august boston scientif submit final technic modul lotu
edg aortic valv system pre-market approv pma applic pave
way fda approv earli conduct survey physician
implant transcathet valv found boston scientif could gain share upon
approv summari find locat page report weight
expect share expect volum physician hospit yield market
share edward abbott
acur transcathet aortic valv boston scientif acquir acur valv
platform symeti acquisit last year acur neo transfemor
system commerci launch europ septemb aim
start clinic studi evalu valv later year studi expect
enrol intermedi high-risk patient random commercially-
avail valv would anticip year enrol patient anoth year
follow-up put potenti approv unit state possibl sometim late
earli estim transcathet valv market today approach
billion size expect market continu grow billion sale
peripher intervent devic boston scientif two key product area
peripher interventionth eluvia sfa drug-elut stent ranger sfa drug-
coat balloon product avail outsid unit state boston scientif
receiv fda approv eluvia septemb boston expect receiv fda
approv ranger dcb believ exist drug-elut peripher stent
market today reason small cook medic privat
compani approv devic zilver unit state believ
could ultim becom billion market estim drug-coat balloon
market nearli million size potenti billion
rezum march acquir nxthera million plu
addit million potenti commerci mileston payment next four
year nxthera primari product rezum system minim invas therapi
treatment benign prostat hyperplasia bph rezum system use water
vapor remov excess prostat tissu therebi allevi obstruct flow
system clear fda ce mark new code
go effect may improv reimburs rezum turn may help
adopt believ rezum potenti grow coupl hundr million
sale compet urolift
cardiac rhythm manag boston scientif plan launch implant
cardiac manag icm monitor diagnost devic plan
launch leadless pacemak eu period product
enabl keep competit abbott
lab current approv product
past five year improv oper margin
compani pois achiev target margin goal
look ahead see continu opportun margin
expans continu cost manag product mix
free cash flow start improv
boston scientif annual free cash flow past decad half
inconsist reflect signific amount special charg year includ
restructur integr litig product liabil like
free cash flow million
product legal tax liabil overhang share past boston
scientif continu sizabl legal liabil reserv billion june
howev view seem likelihood materi upward revis estim
seem low given known underli matter case
year ago boston scientif face risk larg settlement
guidant acquisit women mesh pelvic floor litig still earlier
inning boston scientif incur cash outflow relat settlement
aforement product legal tax liabil reserv though compani set
reserv fund set alreadi amount million thu annual free cash
flow gener go toward fund growth initi includ acquisit
case year eventu resumpt on-going share repurchas program
boston scientif expect organ revenu growth plu
contribut recent manag expect adjust oper margin
increas tax rate expect rang
adjust ep expect rang
septemb provid updat long-rang plan see figur
reflect manag team recent thought end market
incorpor recent close acquisit well milliped expect
acquir manag expect oper constant currenc revenu growth
inclus approxim contribut
though boston scientif note organic/inorgan split still determin
manag expect oper margin improv per year versu prior
guidanc per year manag previous target oper margin
thereaft note due mix dilut associ certain
deal note milliped would prompt compani fall short goal
contribut recent
organ inorgan split tbd base deal size time anniversari
take financi outlook
view one best top-lin growth outlook across larg
cap med-tech sector believ sale could continu surpris upsid expect
manag ep growth low-doubl digit ep forecast
slightli street
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight one
highest sustain sale growth profil larg cap
med-tech compani number new
product across busi segment
provid above-averag growth expect
double-digit ep growth continu believ
premium valuat warrant given
expect growth
upsid case could driven new product
regulatori approv time greater traction new
product improv profit success
integr leverag acquisit
downsid case could driven delay
inabl receiv regulatori approv slower
uptak new product greater competit
pressur key area stent structur
heart greater-than-expect price pressur
conm corp quarterli annual ep usd
consensu number thomson reuter receiv gmt
turnaround success stock initi equal
initi coverag equal weight rate price target
invest stanc turn follow
turn corner seem posit achiev financi goal
view turn corner thank improv execut capabl
thank new manag appoint increas new product
addit surgiquest portfolio manag believ
posit deliv mid-single-digit sale double-digit ep growth rate
could near-term ep risk due higher tax rate believ
street sale forecast reason million vs estim million
street ep estim vs estim may prove high
believ doubl digit rate growth could difficult given tax comparison fx
stock may need time grow current multipl share
appreci year-to-d basi octob compani
outperform top-lin basi rais ep expect view
addit consist result need signific expans occur
valuat risk
set price target use combin ev/sal forward price-to-earnings
methodolog use estim trade ev/sal basi
pe basi sinc share trade averag sale
ntm pe basi given improv growth believ premium multipl
histor averag appropri extent consist revenu growth continu
ev/sal multipl could rise ev/sal multipl would impli valuat given
ep growth rate like low doubl digit believ
pe multipl unlik expand could contract given premium
small/mid-cap med-tech stock histor med-tech trade rang multipl
would impli valu around deriv pt weigh equal
risk relat achiev earn estim price target object
includ continu growth particularli us orthoped new product approv
advers foreign exchang rate competit product launch regulatori action
chang reimburs
price pe histori
compani sale product group
compani sale geographi
midst turnaround past four year proxi fight
attempt gain control compani curt hartman appoint
perman presid ceo novemb sinc hartman orchestr
turnaround plan led appoint sever new execut acquisit
surgiquest time acceler sale growth see figur
conm gener surgeri segment revenu total million repres
total sale sale constant currenc basi period
segment sell endoscop technolog critic care monitor devic
devic focus minim invas laparoscop surgeri began posit inflect
follow acquisit surgiquest would expect airseal sale continu
drive much sale momentum gener surgeri
januari complet acquisit surgiquest million
repres ev ltm revenu multipl approxim surgiquest airseal
surgic access manag system drive sale growth time
acquisit maintain strong double-digit growth control
airseal system consist valve-fre trocar integr insuffl smoke
evacu revenu gener placement airseal box well
sale one-tim use dispos devic much airseal momentum date
come relationship intuit surgic approxim instal
intuit surgic robot accompani airseal devic current manag
estim airseal use approxim robot procedur domest
combin robot larger non-robot laparoscop market howev
manag estim achiev single-digit market penetr
conm orthoped surgeri segment revenu total million repres
total sale sale constant currenc basi period
segment focus sale sport medicin product power instrument
surgic visual system intern busi grown low-singl
digit major last two year domest busi struggl
time period sale declin throughout segment
struggl recent year particularli domest due stale product offer
limit invest new leadership introduct sever new product
help busi return growth begin
spent last two year increas invest bring new
product market launch five new product launch new
product revenu new product also increas
approxim would expect cadenc continu
manag commit increas spend percentag sale
guidanc sale would expect manag continu
increas spend toward high end rang time
histor research develop spend percent sale
financi outlook take
full-year anticip constant currenc sale growth
adjust ep manag expect gross margin
improv expens sale tax rate
longer term manag believ compani consist gener mid-single-digit
top-lin growth double-digit earn growth look consensu
current project top-lin growth adjust ep growth line
manag long-term view howev believ street like miss-
model futur tax rate tax rate reflect benefit discret tax
item belgium tax reform expect repeat contribut roughli
per share earn benefit creat headwind period
model ep versu street
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight success
execut turnaround posit deliv
mid-single-digit sale double-digit ep growth
howev believ valuat appropri
reflect outlook believ could
downsid risk consensu ep estim
due higher tax rate
upsid case could driven continu
success drive mid singl digit sale growth
continu strengthen us orthoped
improv new product contribut
greater expect
downsid case could driven slowdown
organ growth comp becom difficult
slowdown hospit capit equip market
invest spend drive futur growth
foreign exchang rate strengthen us dollar
higher tax
edward lifesci corp ew quarterli annual ep usd
consensu number thomson reuter receiv gmt
under-perform
initi coverag edward lifesci ew underweight rate price
target invest stanc turn follow
edward success tavr undisput there competit ahead
edward lifesci transform ugli duckl time spin-
baxter earli darl success transcathet
aortic valv program today edward leader transcathet valv market
best-sel transcathet aortic valv sapien howev compani
face addit competit come year boston scientif abbott
appear pois enter market respect transcathet
valv survey suggest edward like lose market share
transcathet mitral tricuspid tmt valv could second act time
tell opportun unfold tmt repres area futur growth
edward compani multipl shot goal area sever
program seem promis still earli stage follow releas
coapt studi ew share appreci back market opportun though
retrac gain believ success transcathet mitral valv
like requir ew share maintain current pe multipl
believ multipl may compress tavr slow ew share trade
ep estim believ multipl may compress given slower growth
greater competit transcathet valv market
valuat risk
set price target primarili reli forward price-to-earnings methodolog
pt appli multipl ep estim ew share trade
ep estim believ multipl may compress given slower growth
greater competit transcathet valv market
risk relat achiev earn estim price target object
includ mileston achiev relat transcathet mitral valv program
competit tavr risk includ advers foreign exchang rate competit
product launch regulatori action chang reimburs
ew price pe histori
compani sale product group
compani sale geographi
trans-cathet heart heart valv barclay medic suppli devic
transcathet aortic valv replac tavr fuell top-lin growth
human heart four valv control flow blood one direct
chamber heart mitral tricuspid valv control blood flow
atria ventricl wherea aortic pulmon valv control blood flow
ventricl valv becom stenot narrow regurgit leaki
caus blood flow becom restrict flow backward heart histor
replac repair valv done invas surgic approach
wherebi surgeon would perform sternotomi incis across breast bone
sterum patient would place heart-lung bypass machin
procedur would take place transcathet approach pioneer past two
decad repres less invas patient better solut
common approach transfemor approach wherebi cathet insert
incis leg
edward long leader surgic heart valv market earli pioneer
area transcathet heart valv edward lifesci acquir percutan valv
technolog pvt januari million cash plu addit
million mileston payment view one best acquisit histori
med-tech pvt provid technolog patent bring sapien transcathet
heart valv platform market
sapien valv receiv ce mark european approv septemb
approv us fda novemb compani launch two iter
sapien xt
latest sapien sapien famili balloon-expand
transcathet aortic valv replac tavr system edward also self-expand
tavr system centera receiv ce mark european approv februari
octob edward initi us pivot trial centera believ could
ultim lead approv late depend durat enrol
transcathet valv franchis propel edward sale billion
billion latter includ billion transcathet valv sale figur
photo courtesi
tavr lead expans margin profit cash flow
introduct transcathet valv also posit impact edward
margin profit cash flow profil
tavr market growth outlook favor
estim tavr market approach billion expect continu grow
next five year surpass billion sale market growth expect come
continu adopt technolog exist indic well adopt
low surgic risk patient tavr origin indic use patient sick
treat surgic deem high risk death indic subsequ
expand includ call intermedi risk patient success trial result
edward other current evalu tavr low risk patient popul
edward low risk studi result expect releas american
colleg cardiolog confer march extent trial other
posit believ market expect case tavr
continu see sale growth technolog penetr lower risk popul
edward also evalu use tavr asymptomat patient sever calcif
aortic stenosi earli tavr trial favor market trend benefit edward
compani exposur tavr market
edward futur success turn abil fend tavr competit
outlook tavr market growth favor competit environ
like becom challeng edward addit competitor
launch market boston scientif two tavr deviceslotu acur
approv europ though lotu current hold work
technic issu deliveri system plan re-launch lotu
intern market expect fda approv earli boston also
start us pivot trial acur year pave way fda
approv estim abbott portico tavr valv receiv ce mark
abbott expect fda approv edward certainli stand still
plan launch sapien ultra europ later year sapien ultra
system incorpor textur pet skirt design taller valv
also sheath compat valv size edward also plan launch centera
valv us estim could late time period
flow includesnet relat patent litig barclay medic suppli devic
conduct survey transcathet valv implant physician summari
find illustr particular number physician
indic would incorpor new valv practic weight
expect share expect volum physician hospit yield market
share edward abbott
detail tavr survey pleas turn page report
note weight base expect volum
note weight base expect volum
view survey find present risk edward intermediate-term growth
outlook continu expect transcathet aortic market expand
addit label indic edward share posit may erod potenti lead slight
flatli revenu next sever year new player enter market
transcathet mitral tricuspid therapi next wave growth
edward activ research transcathet mitral valv therapi date back
least earli edward acquir percutan mitral valv repair program
jome februari even acquisit pvt complement
exist program edward also acquir asset percutan mitral valv
program sinc edward acquir cardiaq valv technolog
valtech cardio harpoon medic acquisit valtech
one approv deviceth cardioband system receiv ce mark
european approv septemb
demograph suggest transcathet mitral tricuspid therapi tmtt market could
larger tavr market edward estim million patient
us alon moder sever mitral regurgit mr tricuspid regurgit
tr moreov estim today patient signific mr tr
treat us edward estim tmtt global market opportun could
billion size surpass billion frame refer estim
abbott transcathet mitral valv repair mitraclip sale roughli million last
year around million year
figur illustr edward transcathet mitral program
edward transcathet mitral valv program develop
transcathet devic aim reduc mitral
regurgit annular reduct edward obtain devic
acquisit valtech edward paid million stock cash valtech
potenti million pre-specifi milestone-driven payment
ten year period cardioband mitral reconstruct system receiv ce mark
european approv septemb edward current market product
outsid unit state edward expect sale cardioband mitral tricuspid
indic reach million sale year edward current enrol
activ pivot trial assess tmv repair edward cardioband system
guidelin direct medic therapi gdmt gdmt alon trial includ
patient random treatment control primari endpoint
studi preval mr less hierarch comparison includ
cardiovascular death heart failur hospit improv minut walk
test kansa citi cardiomyopathi questionair kccq point estim primari
complet date per clinicaltri gov septemb could put us approv
sometim late howev trial enrol timelin could prove
challeng light favor coapt trial and/or trial design could
adapt light coapt could push fda approv
pascal pascal system design mitral valv leaflet repair system
includ spacer paddl clasp mitral valv leaflet ce
mark trial clasp underway edward anticip eu launch
studi single-arm studi look enrol patient edward continu
treat patient us earli feasibl studi per clinicaltri gov studi
estim primari complet date juli estim studi complet
date august edward start us pivot studi within next year could
lead potenti us approv earli estim
harpoon edward acquir harpoon medic harpoon devic decemb
harpoon devic design facilit echo-guid repair mitral valv
regurgit stabil prolaps mitral valv leaflet restor proper
coaptat valv function harpoon receiv ce mark edward plan
launch product pend evalu earli complic seen
devic edward start us pivot studi within next year could lead
potenti us approv earli estim
cardiaq cardiaq mitral valv replac system includ trileaflet bovin
pericardi tissu valv self-expand nitinol frame edward work system
enhanc includ reduct valv profil transept deliveri system
compani continu enrol us earli feasibl studi
sapien sapien mitral valv replac system leverag edward
sapien aortic valv platform system compris dock devic
sapien valv dock devic encircl nativ mitral leaflet secur
system allow treatment wide rang annulu size devic
current earli feasibl studi us current patient enrol
across four particip site patient popul saw reduct mitral
regurgit mild trace day
edward also sever program develop area transcathet
tricuspid valv repair ttvt shown
edward transcathet tricuspid program develop
cardioband system design implant techniqu use
cardioband mitral system edward receiv ce mark cardioband tricuspid
valv reconstruct april mark first transcathet therapi
approv treatment tricuspid regurgit edward
plan
commerci product later year edward expect enrol earli
feasibl studi unit state
pascal edward pascal devic use tricuspid repair data
report use pascal compassion use experi devic
use high-risk inoper patient symptomat sever tricuspid
regurgit devic success place patient seven
patient receiv two devic four patient receiv one devic one
death day post-procedur complic observ implant
patient show least one class reduct nyha classif system
class iv pre procedur vs class ii post procedur
forma edward forma tricuspid valv repair system consist foam-
fill polym balloon spacer rail anchor right ventricular apex
edward modifi system anticip resum implant
devic year new system includ spacer steerabl
guid sheath accur anchor placement redesign deliveri system
predict anchor per
clinicaltri gov earli feasibl trial forma tricuspid transcathet repair
system estim reach primari complet date januari estim
studi complet januari
view edward compani greatest success tavr
necessarili mean compani greatest success tmtt
transcathet mitral valv market failur success year
recent tct meet present estim compani
evalu mitral program highlight signific program
edward lifesci expect achiev higher end sale guidanc
rang billion compani also expect ep rang
consensu sale ep expect edward expect
issu guidanc upcom analyst day decemb forecast
street believ transcathet valv expect may lower
compani like continue/acceler invest spend transcathet
mitral valv program forecast notabl street
continu expect competit suppress tavr growth expect mitral
opportun significantli ramp sever year
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ sale growth like
slow edward face competit transcathet
aortic valv tavr expect limit leverag
edward invest transcathet mitral valv
tmvr/r opportun sale ep estim
street tmvr/r repres potenti
second act still risk like
upsid case may driven better-than-
expect tavr sale greater leverag
stronger uptak tmvr europ faster-
than-expect time tmvr/r product
downsid case may driven delay
inabl commerci tmvr/r technolog
slowdown tavr sale due market slowdown
and/or competit pressur fx rate
greater expens support tmvr/r
hill-rom hold inc quarterli annual ep usd
consensu number thomson reuter receiv gmt
lack convict sale acceler initi equal
initi hill-rom equal weight rate price target
invest stanc turn follow
hill-rom diversifi portfolio past five year hill-rom
improv diversif busi less expos hospit capit
equip trend encourag compani futur strategi like
continu approach
underli sale growth may requir invest hill-rom core
sale growth remain level past three year
hill-rom estim sale core basi adjust fx
acquisit divestitur exit non-strateg assets/product line fiscal
hill-rom expect core revenu growth long-rang plan
hill-rom expect core revenu growth acceler closer
believ risk acceler view addit invest
may requir achiev higher growth profil weight averag market
growth rate compani around
believ street may high fiscal fiscal hill-rom
benefit lower tax rate look ahead fiscal expect rise
tax rate pressur earn fiscal ep estim street
valuat risk
set price target primarili reli forward price-to-earnings methodolog
price target appli market multipl calendar year ep estim
sinc share trade averag market multipl believ
histor averag appropri
risk relat achiev earn estim price target object
includ new product approv uptak new product advers foreign exchang
rate competit product launch regulatori action chang reimburs
extent compani success acceler core growth premium
valuat may warrant
price pe histori
compani sale product group
compani sale geographi
patient support line barclay medic suppli devic
like hill-rom shift mix beyond bed
hill-rom formerli complet spin-off funer servic
busi oper name batesvil casket march creat pure-
play med-tech compani time spin hill-rom revenu predominantli
patient support system medic bed product consid capit equip
throughout year compani purpos diversifi busi away capit
equip signific acquisit welch allyn septemb
billion notabl acquisit includ aspen surgic product million
trumpf medic million mortara instrument million
next two year hill-rom expect percent revenu tie capit
reduc reflect mix busi new product
capit revenu total revenu
includ medsurg specialti frame sold acut care set
hill-rom aim acceler core revenu growth
illustr figur hill-rom revenu perform quit volatil mainli
reflect compani capit equip exposur
note adjust acquisit period core growth ex-exit well
past two year hill-rom estim sale core basi
adjust fx acquisit divestitur exit non-strateg assets/product line
fiscal hill-rom expect constant currenc revenu growth core
revenu growth
novemb hill-rom provid long-rang plan lrp includ sale
growth margin ep aspir manag subsequ updat
lrp reflect tax reform legisl summar lrp figur
revenu exclud foreign currenc divestitur exit non-strateg asset third-parti rental third-
manag expect core revenu defin revenu exclud fx acquisit
divestitur exit non-strateg asset acceler compound-annual-growth-rate
given year core like come around would
suggest compound-annual-growth-rate would need closer level achiev forecast
acceler expect come steadi cadenc new product partnership
throughout lrp period divis
patient support system pss expect grow gavr report
basi core basi period growth driven
low mid-singl digit growth patient handl clinic workflow solut
busi new product exit low-margin third parti busi pss
segment grew core revenu first nine month fiscal
front line flc expect grow compound-annual-growth-rate
new product introduct expans compani ambulatori care portfolio
surgic solut ss expect grow compound-annual-growth-rate
continu placement integr tabl motion ts surgic tabl
new product expect help lift core growth rate
hill-rom expect gener million new product fiscal
million fiscal million fiscal major
new product report within front line segment centrella smart
medsurg bed key driver within patient support system integr tabl motion
drive growth surgic solut manag provid guidanc fiscal
million revenu new product compani gener million
nine month fiscal year track well outpac guidanc
new product contribut guidanc growth year-to-d core revenu
growth year remain low singl digit impli weak base
busi estim approxim new product addit
cannib current product line estim base busi flat
slightli neg first nine month fiscal believ long-term
valu mani new product recent soon launch question whether
base busi return growth
much core pss growth lrp driven introduct
centrella smart medsurg bed believ continu strength centrella bed launch
like lead pull revenu mobil nurs call linq mobil
integr technolog imbed centrella bed system
centrella smart medsurg bed system within pss key driver centrella bed
launch began fall manag believ acceler
replac cycl us bed design new technolog enabl
nurses/physician better prevent patient fall enhanc surfac help
reduc pressur ulcer skin deterior issu centrella gener
million revenu sinc launch bed account us medsurg
revenu order size two time histor averag strong order book
linq mobil linq mobil smart phone applic integr clinic
workflow nurs call clinic surveil monitor system improv care-
team collabor commun effici
watchcar incontin watchcar incontin monitor intend detect
provid time alert patient skin expos urin liquid fecal matter
current approxim million incontin pad sold us
annual revenu million product yet launch
mobil nursecal hill-rom estim us nurs call market approxim
million mobil market repres increment million
lrp hill-rom expect front line revenu growth expect
function number new product introduct along improv
perform mortara instrument acquisit hill-rom acquir mortara
instrument februari million cash consider mortara provid
diagnost cardiolog patient monitor acut care primari care clinic
research organ mortara grow sale compound-annual-growth-rate
eight new product introduc integr mortara sale
forc led hiccup sale total sale come slightli guidanc
million manag note busi hit stride fiscal
expect grow mid-single-digit rang
front line far shot goal new product perspect
new product launch flc segment
manag believ potenti combin market potenti
vision screener vision screener handheld devic design
quickli detect vision issu patient young six month old hill-rom
focus market effort improv earli detect amblyopia
vision disabl children
connex monitor launch march connex monitor vital
sign monitor platform provid blood pressur measur puls oximetri
temperatur one devic
retinavu retinavu network welch allyn acquir hubbl telemed januari
hubbl telemed call retinavu network combin
softwar specialist network allow point-of-car retin scan detect
diabet retinopathi encrypt scan sent state-licens board certifi
opthalmologiest turn send physician diagnost report fundu imag
code recommend referr care plan scan complet
process typic complet minut retinavu imag launch
march hand held fundu camera low power microscop camera
use photograph retina cost approxim less tradit
desktop fundu camera manag size us diabet popul
approxim million believ retinavu could becom million-plu per
year product hill-rom announc new partnership siemen healthin
market leader test us retinavu imag includ suit
diabet instrument provid proactiv test treatment singl visit
product gener revenu sale devic well fee per
screen devic use scan patient fiscal estim
current scan closer per quarter
provid accur result second hill-rom believ product repres
million market potenti note six million home blood pressur
monitor sold annual us retail market on-line
monarch airway clearanc system monarch vest launch april
next gener airway clearanc system follow visivest vest use
pulmonari oscil disc pod contain magnet creat kinet energi
kinet energi gener airflow help thin mobil mucu small
airway larger airway cough suction monarch
vest batteri power use lte connect elimin need
patient manual record therapi session sever compet vest
market though mani requir patient remain seat attach pulsat
therapi unit ptu monarch vest uniqu use lte/wifi also
uniqu use magnet gener energi limit use patient without
pacemak implant cardiovert defibril
lrp hill-rom expect grow surgic solut busi rate
two new products/relationship expect contribut growth
integr tabl motion hill-rom intuit surgic receiv clearanc
offer integr tabl motion itm da vinci xi surgic system us
januari trusystem design connect da vinci xi
surgic system order allow dynam patient posit surgeri part
agreement intuit offer itm softwar part
da vinci xi sale process softwar sale success hill-rom sale rep
respons close final sale itm tabl current approxim
da vinci xi robot sold itm softwar high convers
rate manag note still larg uninstal base present
opportun itm gener approxim million ad
overal growth itm sale expect grow
imri partnership novemb hill-rom imri instal imri
announc fda clearanc multi-funct mri condit tabl design
imri surgic theatr tabl integr imri neuro tabletop hill-rom
trusystem surgic tabl platform partnership provid hill-rom initi
foothold hybrid oper room market imri current instal pend
surgic theatr north america europ middl east asia australia hill-rom
yet meaning penetr current instal base believ financi
impact partnership like mute given size imri hybrid
space refer geting instal hybrid novemb
hill-rom target margin expans double-digit ep growth lrp
illustr figur hill-rom lrp target continu gross oper margin
improv gross margin expect expand
much improv come improv product mix compani
exit lower margin third parti busi increas sale new product hill-rom
expect oper margin expand
addit leverag gross margin improv hill-rom also expect
benefit cost disciplin overhead optim sg line expens
expect remain stabl percent sale
top line combin margin expans provid double-digit
ep growth lrp assum effect tax rate manag expect
gener billion cumul oper cash flow plan
fund cumul capital-expenditure million delev balanc sheet target leverag
less plan increas dividend
revenu exclud foreign currenc divestitur exit non-strateg asset third-parti rental third-
cumul
take financi outlook
fiscal hill-rom expect report revenu growth constant currenc
revenu growth core revenu growth would impli
revenu growth report constant currenc basi along core growth
manag expect achiev gross margin expans
oper margin improv full-year adjust ep expect
rang street per thomson current higher end
rang
street estim seem bit high fiscal
believ hill-rom upcom financi guidanc could consensu
estim top bottom line
sale outlook current thomson reuter consensu estim includ
total revenu billion consensu revenu estim impli nomin
growth adjust million non-strateg product exit consensu impli
core growth closer given hill-rom grown core busi last
two year view approxim acceler lower probabl outcom
earn outlook current thomson reuter consensu ep estim
seem high us model ep believ
margin expans assumpt overli conserv current
forecast oper margin expans consist gross margin
improv reduct sg margin assum tax rate normal
level consist long rang plan year guidanc
model ep line consensu
equal weight view compani may
continu struggl increas core sale growth
 may necessari ep
estim seem reason think street may
littl high valuat
seem fair outlook
rate driven new product introduct better-
than-expect margin improv
downsid case driver includ challeng
hospit capital-expenditure environ inabl drive
acceler top-lin growth increas
competit pressur dilut
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
medtron plc quarterli annual ep usd
consensu number thomson reuter receiv gmt
valuat still attract despit recent initi
initi coverag overweight rate price target
invest stanc turn follow
believ execut plan view execut
stori compani mix track record histor believ
manag tool incent get right go forward
mid-single-digit sale high-single-digit ep growth seem like expect
medtron top-lin growth come combin end-market growth along
benefit new technolog june investor day manag
provid expect growth target organ sale growth
annual oper margin expans constant currenc basi ep growth
least believ medtron achiev exceed baselin goal
despit recent appreci valuat remain attract share
year-to-d octob compani execut
plan provid updat long-rang plan analyst day june believ
trade closer sector histor averag expect pe
multipl expand
valuat risk
set price target primarili reli forward price-to-earnings methodolog
price target appli target pe calendar ep estim
sinc med-tech sector trade averag premium market
execut plan market gain confid abil deliv
believ pe multipl expand closer histor averag
risk relat achiev earn estim price target object
competit product launch regulatori action chang reimburs success
integr dilut
price pe histori
compani sale product group
compani sale geographi
global leader med-tech
sale nearli billion largest med-tech compani
sale growth come intern well acquisit notabl
deal sofamor danek spine arteri vascular engin vascular
minim diabet notabl covidien surgic
new product improv execut improv organ growth
past two decad sale earn growth rate slow owe
matur mani key market cardiac rhythm manag spine
coronari stent coupl misstep execut side slowest period
growth period sale sinc
sale growth acceler mid-singl digit attribut acceler
new product improv execut also underli improv overal
note adjust major acquisit extra sell week
june investor day manag state goal deliv
organ sale growth view abl deliv goal
come littl ahead consid end-market growth rate along benefit
new technolog plan introduc come year
notabl new product illustr figur includ
micra leadless pacemak receiv fda approv micra leadless
pacemak april though last year first full fiscal year reimburs
exit year sale annual well million revenu
product today individu need single-chamb pacemak
estim pacemak popul howev compani develop
next-gener version expand address market entir
pacemak commun micra one-tenth size tradit pacemak
implant via minim invas approach target releas
micra av end fiscal expand market applic
half market
expect product launch beyond
transcathet valv continu develop next-gener transcathet
aortic valv replac tavr technolog next gener evolut plan
well new platform dub horizon compani also seek expand
indic use low surgic risk patient popul product
expand indic ensur continu double-digit growth tavr
busi forese futur also develop transcathet
system treat mitral valv octob receiv fda approv
start apollo transcathet mitral valv replac trial evalu intrepid
valv enrol underway site activ medtron plan
incorpor transfemor transsept deliveri system around end calendar
year earli next accord clinicaltri gov studi enrol
particip primari outcom measur all-caus mortal stroke
reoper reintervent cardiovascular hospit year moreov
estim primari outcom complet date project octob
suggest potenti approv still sever year away
surgic robot medtron legaci covidien robot platform date back januari
past sever year compani devot signific amount
resourc bring product market earlier year announc
timelin would delay work system featur medtron current
timelin advanc system clinic fiscal launch
occur fiscal essenti one year later initi plan johnson johnson
also target market launch verb surgic platform partnership verili
alphabet/googl robot surgeri market pioneer intuit
surgic sale expect approach billion year thomson reuter estim
renal denerv renal denerv back potenti five year ago
signific enthusiasm around multi-billion dollar market prospect renal
denervationth ablat renal arteri reduc blood pressur level
patient hypertens three major cardiac compani boston
scientif st jude renal denerv program place acquir
program million ardian deal acquir
million plu mileston million vessix deal
market enthusiasm significantli cool announc januari
symplic trial fail meet primari endpoint medtron
went back draw board attempt anoth shot redesign
symplic spyral system april receiv fda approv start
patient trial latest european data use symplic spryal system seem
encourag though time tell multi-billion opportun resurrect
diabet follow earlier-than-expect approv june launch
expect diabet group gener doubl digit growth throughout
howev suppli constraint relat associ guardian connect
continu glucos monitor cgm sensor well shipment relat
compani prioriti access program limit initi uptak lead declin
diabet revenu issu prove transitori diabet segment
sale inflect octob anima johnson johnson announc
exit north american pump busi name partner
choic anima patient approxim manag view
roll-out still earli inning current control insulin
pump market manag estim market approxim
penetr also receiv ce mark expand indic
treat patient type diabet young seven year old june
provid addit runway growth also see
increas cgm sensor util attach rate driver continu sale
growth go forward also launch first stand-alon gcm guardian
connect sugar iq june stand-alon cgm market approxim
billion size today
fx weigh oper margin expans ep growth
medtron sale geograph divers sale unit state
non-u develop market emerg market thu foreign exchang
rate movement signific impact report result
one area investor focu past year medtron oper
margin perform fx obscur compani underli oper margin
expans part driven achiev million cost
synergi relat covidien acquisit
past three year fiscal net fx includ impact hedg
cumul million headwind sale impact oper margin
million impact net incom per share
fx impact medtron financi result
impact op margin
fiscal current expect fx headwind million
top line posit impact oper margin due hedg gain
neutral ep current guidanc less favor origin fiscal guidanc
issu may includ currenc headwind million top line
favor per share bottom line
fx asid enterpris excel provid margin expans
previous mention oper margin perform point
focu investor past year compani spot execut
margin expans currenc repres major headwind period
june investor day manag provid expect annual
oper margin expans constant currenc basi heart
expans target enterpris excel program announc januari
enterpris excel program aim reduc cost billion fiscal
increment annual gross run-rat save expect million
rang fiscal period identifi three area save
global oper strategi would includ standard best practic
optim qualiti deliveri cost cash flow across manufactur suppli chain
administr facil also includ network optim strateg sourc
save gener vector primarili seen cost good sold
help off-set annual price pressur seen across busi
global function optim includ transform improv product
employe experi area like financ human resourc legal inform
technolog sourc qualiti aim enhanc leverag global
oper model system like share servic save materi cost
good sold sg line
global commerci optim would includ save target evolv
go-to-market model enhanc autom sale process transact
improv product consolid certain common oper
system save vector primarili seen sg line
along fiscal result manag provid updat fiscal
guidanc expect organ revenu growth manag
express confid high end rang foreign exchang rate expect
reduc sale million result impli revenu rang
billion manag expect constant currenc oper margin expans
foreign exchang expect add addit result impli
oper margin bottom line manag expect ep
incorpor neutral impact currenc
septemb announc intend acquir remain stake
mazor billion total gross deal valu billion medtron manag
comment expect acquisit close medtron third fiscal quarter
end januari moreov manag comment expect
acquisit modestli dilut fiscal adjust ep given
current strength underli busi compani expect absorb dilut
analyst day june manag provid updat longer
term expect manag expect drive least organ revenu growth
incorpor view develop market grow emerg market grow
low double-digit busi group expect cardiac vascular group cvg
minim invas therapi group mitg restor therapi group rtg grow
line corpor averag diabet expect grow faster manag
expect sustain annual underli oper margin expans rang
net/net manag expect adjust ep growth
take financi outlook
includ acquisit mazor sale earn forecast board
director compani unanim approv transact pave way
ultim close ep estim slightli street attribut
assumpt fx like slightli greater impact result
market expect
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ
number new product across busi
allow sustain mid-single-digit growth
expect leverag provid
least high-single-digit ep growth believ
stock valuat still attract despit recent
appreci share
upsid case driver includ success
deploy market share gain key area
cardiovascular structur heart surgic
neurostimul greater margin expans
expect
inabl receiv product approv market
share loss key categori dilut deal
stryker corp quarterli annual ep usd
consensu number thomson reuter receiv gmt
diversifi growth stori remain intact initi
initi coverag overweight rate price target
view diversifi growth stori remain firmli intact believ stock
warrant premium valuat overweight rate base view
sustain above-sector-averag revenu growth believ
attract mix busi thank acquisit strategi past decad
compani built attract franchis area orthoped medsurg equip
neurotechnolog spine given mix busi product
outlook believ averag revenu growth sustain
abil drive leverag bottom line long-term goal
includ commit drive least basi point oper margin
expans deliv floor target ep growth believ compani
cost transform program help achiev goal
durabl growth warrant premium valuat believ durabl
growth among highest within medic devic believ premium
valuat warrant
valuat risk
set price target primarili reli forward price-to-earnings methodolog
price target appli pe multipl ep estim believ
rel premium valuat multipl sustain given above-p growth
prospect sinc averag rel pe premium price target
assum rel target pe use barclay target market multipl
risk relat achiev earn estim price target object
includ continu sustain knee franchis new product approv
advers foreign exchang rate competit product launch regulatori action
chang reimburs
price pe histori
compani sale product group
compani sale geographi
well-diversifi growth aid strateg
nearli histori diversifi growth compani compani
significantli increas weight orthoped billion acquisit
howmedica increas weight orthoped help strengthen
compani underli growth rate begin late continu
busi slow significantli owe declin medsurg equip
busi driven hospit capital-expenditure market freez well slower orthoped sale
begin embark upon journey strengthen core
diversifi revenu base figur illustr compani
acquisit histori view track record acquisit posit deal
contribut underli improv growth compani
organ growthorthoped slow hospit capital-expenditure busi face ascent healthcar solut reprocess gaymar industri sonopet asset synerget asset porex neuro-vascular busi memomet concentr medic orthovita mako patient safeti technolog hold pivot medic small bone innov coalign chghospit bed muka product physio-control synerget neuroportfolio stanmor implant world-wide vcf asset bd safewir ivi sport medicin restor surgic novadaq safeair ag hyperbranch pend barclay medic suppli devic
shown figur sale mix becom diversifi less expos
capit equip orthoped busi weight reduc
sale respect period medsurg weight
increas sale signific decreas capit equip
neurotechnolog spine weight increas
orthoped pois continu growth mako differenti
stryker orthoped segment revenu total million repres total
sale sale organ basi maintain
steadi mid-single-digit high-single-digit growth larg due market lead growth
knee busi well consist growth trauma extrem unit
makohelp separ peer
acquir mako surgic corp decemb million repres
ev ltm revenu multipl ev ntm revenu multipl
mako rio robot arm system stryker mako approv partial knee
arthroplasti pka total hip arthroplasti tha time acquisit
receiv clearanc total knee tka applic initi
limit launch march wait march full roll-out follow
launch began consist grow sever hundr basi point market
quarter note launch cementless knee also help knee growth
compani continu increas number train surgeon quarter
train manag estim us hospit
orthoped practic approxim half candid least one robot
mako robot nearli us hospit leav signific room
addit expans even take account competit zimmer biomet rosa platform
expect begin limit launch johnson johnson orthotaxi platform
expect launch
orthoped survey show continu adopt robot technolog
survey orthoped surgeon gaug recept robotic-assist technolog
summari survey result figur page survey show
number surgeon plan train and/or use robotic-assist system expect
significantli increas next year see figur figur surgeon
also expect increas number procedur use robotic-assist system
repres largest share see figur figur view
result bode well knee outlook
surgeon use robotic-assist system total knee
expect use robot total knee arthroplasti
note result weight expect total knee arthroplasti volum
surgeon plan train use robotic-assist
total knee year
expect use robot total knee arthroplasti
note result weight expect total knee arthroplasti volum
extrem sub-seg steadi double-digit growth engin within
orthoped segment last five year much growth come build
foot ankl busi compani use acquisit memomet
catalyst set dedic foot ankl sale forc continu build
product portfolio intern develop small bone innov
estim market leader lower extrem
also begun build dedic sale forc upper extrem portfolio
late focus build shoulder offer estim stryker
shoulder market share remain rel low believ catalyst
next leg growth extrem segment
gener plu organ growth medsurg segment last two
year driven intern product innov contribut acquisit
anniversari segment gener million revenu
repres sale sale constant currenc basi
organ
instrument sub-seg compris primarili surgic equip navig
system gener million revenu repres constant currenc
growth much sub-seg growth driven launch
gener power tool would expect launch continu support
strong growth
septemb announc agreement acquir invuiti inc per
share approxim million impli enterpris valu approxim
million impli ev-to-sal multipl use consensu revenu
estim million view valuat reason given invuiti high-teen
growth expect stryker least sustain growth fulli integr
invuiti intellig photon product provid improv visibl minim invas
surgeri across women health orthoped spine electrophysiolog segment
endoscopi sub-seg gener million sale repres
constant currenc growth segment growth recent year driven primarili
launch aim surgic video platform launch decemb would
estim strength begin wane end howev
would expect expect launch next gener surgic video
platform well acquisit novadaq close septemb
provid support sub-seg organ growth
medic sale total million repres growth constant
currenc basi segment histor predominantli capit sale patient
handl emerg medic equip diversifi segment reduc
top-lin volatil associ capit sale end made number
acquisit two signific one product physio-control
complet acquisit product billion april
sale total million consist dispos product focus reduc
hospit acquir condit never event icu medsurg hospit unit
set compani grow low-teen howev compani
sever recal lead declin sale juli recal one lot
comfort shield cloth subsequ expand juli receiv
warn letter relat oral solut august initi recal
specif lot oral product put temporari hold cloth-bas product
resum ship octob continu feel impact
recal sale declin year-after-year expect return growth
pre-recal level would expect return take sever quarter play
april complet acquisit physio-control intern physio
billion fiscal revenu million physio manufactur
monitors/defibril cpr assist devic along data manag
support servic compani sale approxim capital/dispos
servic physio recal lifepak defibril januari howev busi
sinc recov accret segment organ growth
neurotechnolog spine expect continu strong growth ahead
gener high-singl digit organ growth neurotechnolog spine
segment last three year larg driven strong product innov market
growth within neurotechnolog combin segment gener million
revenu repres total sale segment grew constant
currenc organ look ahead expect continu strong growth
driven neurotechnolog market segment also benefit contribut
entellu
neurotechnolog sub-seg gener million sale repres
constant currenc growth much growth neurotechnolog segment
attribut neurovascular product target coil acut
ischem stroke product growth also driven craniomaxillofaci cmf
product neuro power instrument
februari complet acquisit entellu medic
purchas price per share aggreg purchas price million
acquisit expand presenc nose throat ent segment
provid dedic ent sale forc believ entellu franchis
sustain growth high-teen
spine sub-seg gener million sale sale declin
spine market weak sever quarter core spine market
experienc low-to-mid-single-digit declin weak off-set specialti
spine product help gener organ growth
forese turnaround spine market near term would expect
continu reli tritanium intervent spine product drive organ growth
august announc acquisit ktwo
per share impli equiti valu approxim billion enterpris
valu approxim billion gener million ltm revenu
impli ev ltm sale multipl consist view spine core
busi given largest orthoped sub-seg meaning overlap
neurotechnolog busi acquisit bolster product portfolio
complex spine spine deform trauma tumor minim invas approach
schedul sharehold vote acquisit novemb
oper margin flatten recent year there opportun
expans
shown figur oper margin remain fairli flat around
level past four year
compani novemb investor meet manag laid
transform growth plan goal improv oper margin
bp annual plan focus reduc structur non-valu ad cost
continu reinvest innov expand growth platform
due product recal impact hurrican season dilut
associ novadaq acquisit experienc declin oper
margin adjust three factor howev oper margin expand
thu far gener oper margin expans
first two quarter year relat oper improv
relat adopt quarter would anticip strength
continu compani lap tougher comp experienc
believ achiev exceed state financi goal
stryker state long-term financi goal includ grow top line high end
med-tech allow compani drive basi point annual oper margin
improv ep growth least annual
current guidanc includ organ sale growth
adjust ep rang compani expect minimum
oper margin expans expect full-year tax rate fall within rang
look ahead view current consensu estim reason
street current expect sale billion repres nomin revenu growth
adjust ep repres growth follow acquisit
re-affirmed long-term financi aspir includ floor ep
growth
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ sustain
above-sector revenu growth profil see
multipl driver across three busi
believ deliv margin commit
goal least annual drive least
ep growth given outlook believ
premium pe justifi
growth greater success new product
greater success drive oper margin
downsid case driver includ slowdown
orthoped hospit capital-expenditure market increas
competit knee foreign exchang stronger
us dollar inabl drive margin expans
quarterli annual ep usd
consensu number thomson reuter receiv gmt
con leav us sidelin initi
initi coverag equal weight rate price target
initi equal weight believ
urolift provid uplift growth octob acquir neotract
billion transact acquir fast-grow high gross
sale expect grow estim million
sale believ potenti exceed million next five year
expect urolift lift core sale growth rate
revenu acceler proven difficult aim increas
growth rate core sustain though fallen short
rang averag sale compound-annual-growth-rate past three year
street ep estim may high believ fx rise interest
rate like headwind also believ compani like
continu invest behind growth opportun urolift improv core
valuat risk
set price target primarili reli forward price-to-earnings methodolog
price target appli multipl time ep estim sinc
share trade averag market multipl given recent acceler
growth believ premium valuat warrant
risk relat achiev earn estim price target object
includ perform urolift new product approv advers foreign exchang rate
competit product launch regulatori action chang reimburs
price pe histori
compani sale product group
compani sale geographi
evolv diversifi pure-play medic devic compani
past decad significantli transform industri
conglomer pure play med-tech compani acquisit play major role
evolut medic portfolio notabl recent deal
lma vidacar vascular solut
anesthesia surgic urolog product
sale growth perform lag expect
manag goal acceler organ sale growth rate
compani higher mani year past four year averag
compani seen improv new product contribut shown
figur new product cannib exist product
first half organ sale growth seen variat quarter-
to-quart trend due distributor buy pattern
despit top-lin perform achiev margin
despit rel softer organ sale growth rate expect past three year
outperform margin side shown figur
analyst day target execut
impli perform base
bp
bp
target acceler sale growth margin expans
may outlin long-rang plan lrp next three year
period expect averag organ constant currenc revenu growth
rate assum base busi grow rate
vascular solut acquisit add growth neotract add
expect adjust gross margin continu expand
oper margin expand figur
urolift futur growth driver
previous mention urolift contribut per year long-rang
plan octob complet acquisit neotract develop
urolift system million up-front payment plu million conting
mileston expect deal per share accret ep
urolift minim invas technolog treat lower urinari track symptom due
benign prostat hyperplasia bph sale urolift steadili increas
quarterli basi shown figur
expect sale growth million level
believ highli like given momentum first half year
next five year believ urolift sale could grow roughli million driven
continu adopt aid recent inclus urolift standard care option
treatment enlarg prostat american urolog associ aua clinic
guidelin address patient popul larg incid bph
men men men age
us alon million men treat bph though initi focu us
opportun intern opportun equal larg urolift sale
primarili uk today though work reimburs countri
also submit shonin japanes registr worth note
mileston pay-out million base sale target million
risk forecast could competit expect minim invas bph market
becom competit next year receiv improv reimburs
rezum system rezum fundament differ urolift urolift
procedur perman implant place hold open obstruct pathway
block urin flow minim invas transurethr outpati procedur
rezum use water vapour remov excess prostat tissu allevi obstruct flow
rezum clear fda though uptak rezum limit
reimburs despit aua code reimburs committe confirm rezum
treatment report code transurethr destruct prostat
tissu rf therapi payer medicar carrier indic
unlist code procedur urethra significantli
lower reimburs rate effect januari expect new code
vapor thermotherapi destruct prostat tissu rezum
map expect higher propos rate otherwis would
vascular solut inc vsi also favor driver top line
februari acquir vascular solut inc vsi compani
focus minim invas coronari peripher vascular procedur total
purchas price million acquisit price approxim mid-
point vsi financi guidanc million vsi expect add
approxim base gross margin base
oper margin deal also expect add approxim per
share adjust earn
vsi sale histor grew doubl digit acquir vsi made
strateg decis convert vsi distributor direct impact
underli vsi growth howev convers complet vsi sale growth
rate rebound sale legaci vsi busi report
along vsi acquisit acquir re-pla freeze-dri plasma plan
submit biolog licens applic bla re-pla would allow
approv later year estim total market size re-pla
million govern opportun repres million total
approv re-pla could potenti upsid driver forecast compani
note includ modest sale re-pla lrp
take financi outlook
recent hiccup base busi
experienc two issu impact top line caus organ
growth fall lower-than-norm growth within emea due distributor-to-
direct convers within vascular solut reduc order certain us base
distributor impact compani north american-bas busi investor
like view impact distributor-to-direct convers transient impact lower
distributor buy concern
manag note lost volum return
compani post organ growth volum grew
view low somewhat concern consid portion growth relat
catch volum
note weak domest distributor purchas trend caus weaker
expect quarter organ growth volum growth given
extra sell day time issu order would expect
meaning neg impact distributor order pattern remaind
said remain somewhat cautiou forecast base busi
given frequent natur issu late
said view believ long-rang plan lrp achiev albeit
larg depend success neotract franchis lift core organ
growth rate lift gross margin also time lead improv
oper margin profil compani well view street also view lrp
achiev beatabl judg current consensu project
figur figur illustr revenu ep project next three
year estim sale slightli street
respect ep estim street year period
forecast incorpor gross margin vs lrp
oper margin vs lrp model ep
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight believ neotract vsi
howev core growth rate struggl
improv howev ep estim
street believ fx rise interest rate
headwind given believ stock
fairli valu current level
upsid case could driven greater urolift
vsi sale greater improv profit
improv core busi sale growth
rate accret
downsid case could driven slowdown
urolift sale rel expect challeng
within core busi foreign exchang rate
stronger us dollar higher interest rate
quarterli annual ep usd
consensu number thomson reuter receiv gmt
transform like take signific time initi
initi coverag zimmer biomet underweight rate price target
invest stanc turn follow point
modest sale acceler seem like zimmer biomet challeng
manufactur constraint due qualiti system remedi past year
half look ahead expect constraint eas provid zimmer biomet
opportun modestli acceler sale growth also believ number
new product help sale perform come year cementless
prospect new ceo corpor strategi encourag view
bryan hanson appoint ceo posit posit believ bring
zimmer biomet new vision strategi long overdu
there like long road ahead manag character turnaround
restor compani end market growth rate two year process agre
howev ultim compani growth outlook defin end market
compet unfortun zimmer biomet like mean low single-
digit growth believ hanson arch object acceler top-lin
growth mid-singl digit seem possibl increas
invest importantli activ portfolio manag view
transform need stock like see signific appreci
think street ep expect high believ zimmer biomet
may continu see margin pressur slight improv
ep street versu respect ep
estim believ stock multipl unlik expand significantli
current level earn acceler strategi becom clearer
valuat risk
set price target primarili reli forward price-to-earnings
methodolog price target appli multipl time ep estim
risk relat achiev ep estim pt object includ new
regulatori action particularli around warn letter chang reimburs
price pe histori
compani sale product group
compani sale geographi
zimmer biomet one largest orthopaed compani billion sale
zimmer found acquir bristol-my spun
compani histori includ period success year post spin
follow spin-off bristol-my zimmer enjoy number year double-
digit sale growth compani success integr centerpuls acquisit
enjoy favor orthoped environ character posit price
abil drive posit mix
orthoped environ start chang depart justic
launch investig industri sale market practic septemb
zimmer other industri enter defer prosecut agreement
dpa depart justic relat sale practic chang
way compani could interact physician sinc zimmer sale growth
deceler entir orthopaed industri deceler
attribut chang price environmentfrom posit neg
abil drive favor mix also diminish believ chang price
mix dynam part attribut increas transpar cost
relationship brought defer prosecut agreement orthoped volum
also slow result recess impact individu abil pay
elect procedur economi improv ensu year orthoped volum
improv though price environ remain challeng
april zimmer announc would acquir rival biomet billion cash
stock sinc announc close deal june zimmer biomet sale
momentum slow attribut disrupt relat merger past
year half zimmer biomet also challeng qualiti remedi effort
impact compani abil produc suffici suppli product
note sale growth adjust materi acquisit centerpuls biomet sale growth adjust
abbott spine ldr acquisit
new leader take helm enter bryan hanson
decemb zimmer biomet board director appoint bryan hanson
posit presid chief execut offic hanson previous serv
medtron execut vice presid presid medtron minim
therapi group prior hanson serv varieti role covidien
includ group presid medic devic busi
believ chang strategi need becom attract
mr hanson bring wealth experi zimmer biomet believ credibl
choic help turn compani around said view turnaround
need fairli radic overhaul compani strategi end market
weight make invest case attract current level
legaci zimmer strategi stay cours orthoped diversifi
outsid realm legaci zimmer acquisit histori includ orthoped asset
centerpuls acquisit abbott spine unit biomet
strategi zimmer biomet chang major acquisit
ldr spine transact comparison zimmer biomet competitor
taken opposit approach purpos diversifi past decad
challeng big pictur end market zimmer biomet compet
zimmer biomet one largest orthopaed compani billion sale
estim compani weight averag market growth rate wamgr roughli
see figur biomet sale mix predominantli tie major jointship
kneesrepres total sale estim hip knee market
grew around constant currenc basi slightli softer
rate look ahead expect slight improv growth level driven
demograph age popul trend newer technolog robotic-
assist surgeri also assum price trend remain consist current level
per year reimburs chang could present risk longer term
zimmer biomet sale mix estim market growth rate
view believ mr hanson like look shift compani weight
faster growth market portfolio manag march wall street
journal report zimmer biomet retain advisor possibl divest
dental busi http //www wsj com/articles/zimmer-biomet-holdings-considering-
manag comment merit
report howev manag offer comment quarterli earn call
investor present includ desir diversifi growth engin like
subcategori sport extrem trauma set market also comment
past commit spine
strategi activ portfolio manag uniqu med-tech good
compani strategi acquir compani potenti acceler
underli sale growth rate acquir cost-sav synergi think
med-tech landscap compani consid aggress activ portfolio
manag includ baxter avano formerli halyard health differ
compani zimmer biomet balanc sheet june zimmer
biomet net debt billion net debt ltm ebitda adjust approxim
compani expect gener free cash flow year tune
billion billion last year small amount earmark pay dividend
million think much balanc year like go pay debt
net debt ebitda closer zimmer biomet may look use cash flow
 purpos
facilit chang strategi improv base busi
challeng zimmer biomet sale stagnat
shown figur zimmer biomet revenu flat past eight year
combin basi compani struggl sale perspect sinc
announc april close biomet deal june zimmer biomet sale
momentum slow attribut disrupt relat merger past
year half zimmer biomet also challeng qualiti remedi effort
impact compani abil produc suffici suppli product
end result under-perform rel overal market illustr figur
zimmer biomet organ sale versu
note biomet result closest calendar year end forma combin revenu
zimmer biomet sale perform rel market
late fda inspect zimmer biomet north campu manufactur facil
warsaw indiana issu fda inspect observ
inspect observ issu conclus inspect fda
investig observ condit may constitut violat food drug
cosmet fd act relat act april zimmer receiv anoth
relat north campu facil subsequ respond fda
respons august zimmer biomet receiv warn letter fda relat
north campu facil warn letter fda acknowledg
progress made zimmer biomet note outstand defici fda also
propos regulatori meet discuss propos correct
manufactur qualiti remedi effort affect zimmer biomet abil
produc adequ suppli product across knee hip busi unit
compani work improv suppli product anticip eas
constraint year
knee repres zimmer biomet largest sale weight total sale zimmer
biomet lose market share knee previous mention knee
impact suppli constraint result qualiti remedi effort howev also
believ also reflect lack key new product robotic-assist system
next year zimmer biomet competit posit much improv
earlier year zimmer biomet initi launch cementless knee
expect sold premium benefit premium price
cementless knee offer cementless knee repres quarter stryker
knee roll-out cementless knee would expect zimmer biomet
benefit favor product mix
later year zimmer biomet plan limit launch revis system persona
knee system persona success knee line compani avail
revis system help continu adopt premium knee line
also later year zimmer biomet plan limit launch total knee applic
rosa robot platform zimmer biomet acquir rosa robot system
juli acquisit med-tech sa french med-tech compani origin
applic rosa spine compani iter platform use total
knee arthroplasti zimmer biomet expect approv knee total applic
end year limit launch increas impact thereaft
stagnat top line recur special charg impact compani abil
gener improv net incom free cash flow illustr figur legaci zimmer
legaci biomet poor histor free cash flow perform view
note biomet result closest calendar year end estim pro forma combin
potenti solut work reduc recur special charg
improv cash flow prioriti compani zimmer biomet expect gener
free cash flow billion improv billion last year reduc
special charg mainli respons improv biomet merger integr
expens cash non-cash total million million million
respect special item total million million
million respect increas part relat
remedi expens special item expens decreas compani complet
biomet integr plan substanti complet qualiti remedi
conclus transform like take time mani year
believ mr hanson bring need chang strategi
compani avenu zimmer biomet address current challeng
turnaround importantli transform like take substanti amount
time view turnaround current busi like take much next
year prospect grow line market like event
transform like take time previous note rate growth given
zimmer biomet sale weight like believ arch
object manag team acceler top-lin growth mid-
singl digit view achiev transform includ
activ portfolio manag crisp execut
meantim think there still earn risk ahead
street expect zimmer biomet significantli recalibr sinc
middl last year ep estim fall ep estim
fall
current thomson mean ep estim impli
ep growth believ could risk estim due
recent chang foreign currenc also manag desir reinvest busi
gener futur growth ep estim
respect impli modest growth project ep growth also
consensu
assumpt next two year includ view gross margin remain
pressur annual sell price declin creat headwind year product cost
per unit remain high compani devot time toward qualiti system
resolut rather focus manufactur cost reduct initi also believ
cost per unit impact higher level product cost associ
higher bar qualiti system lastli compani continu invest sale
market well drive futur growth
would like view would diversifi compani higher growth
market favor believ could also present risk earn forecast extent
deal dilut
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight view appoint
bryan hanson ceo posit catalyst chang
believ orchestr turnaround
howev believ transform need
like take multipl year sever new product
could help competit posit knee
impact like materi also
upsid case could driven improv
market trend orthoped greater success
improv price trend strateg
downsid case could driven inabl
receiv and/or execut new product approv
deterior price addit fda regulatori
exchang stronger us dollar dilut
conduct survey
shift less invas medicin perpetu theme med-tech
present investor signific market opportun exampl enabl med-tech
devic includ trocar enabl develop laparoscop surgic approach
oppos tradit open surgeri well balloon stent enabl
develop percutan translumin angioplasti versu surgic bypass
earli sever compani acceler develop transcathet valv
technolog less invas approach compar tradit open-heart surgeri
area aortic valv two leader fieldpercutan valv technolog
pvt corevalv acquir pvt januari million
cash plu addit million payment upon key mileston medtron
acquir corevalv april million plu mileston payment
transcathet aortic valv technolog first approv use europ us
european approv may approv us januari
edward sapien valv receiv ce mark approv septemb
approv us novemb
market transcathet aortic valv replac tavr grown significantli
past decad
edward domin leader transcathet aortic market sapien
transcathet aortic valv tri gain share playersinclud
st jude abbott portico jena valv symeti acur direct
medic bankrupt lotusent european market
begin though date limit success attribut lack
clinic data
look ahead expect transcathet valv market becom competit
particularli unit state today edward two
manufactur approv product next three four year sever new
valv could approv use unit state
lotu valv receiv ce mark octob though product
recal octob commerci halt februari
resolv technic manufactur issu august boston scientif
submit final technic modul lotu edg aortic valv system pre-market
approv pma applic pave way fda approv earli
estim
abbott pursu fda approv portico transcathet aortic valv us clinic
trial result expect releas american colleg cardiolog meet
march would expect abbott file pma earli next year believ
approv could come earli late earli abbott expect approv
edward recent initi us pivot trial centera self-expand stent
trial prospect single-arm studi includ approxim patient
includ bicuspid registri studi composit endpoint all-caus death
and/or stroke year believ centera could receiv us approv late
depend enrol timelin
boston scientif anticip start us pivot studi legaci symeti
acur end year believ acur could receiv us
approv late depend enrol timelin
gaug potenti recept new technolog survey physician
survey conclus stock implic
takeaway transcathet valv surgeon survey includ follow
transcathet valv survey conclus stock implic
find stock implic
physician demograph major physician classifi intervent cardiologist physician
evenli split academ commun hospital-bas practic averag
edward sapien valv use patient physician exclus
edwardss sapien valv exclus corevalve/evolut valv
percent case turn
averag physician indic nearli case turn patient
good candid tavr procedur case turn
sick treat follow patient low risk
believ result bode well futur outlook tavr indic still patient
could benefit earlier detect well expans low risk popul
expans low risk ask physician base publicli avail data pleas provid thought whether
believ tavr implant low risk patient physician believ tavr
use low risk patient
physician report patient prohibit risk surgeri consid high
surgic risk deem intermedi risk consid low surgic risk
data suggest us like addit patient becom elig tavr
procedur upon label expans market may necessarili see signific step
function growth lower-risk patient alreadi receiv treatment today
averag physician expect growth volum period
interest next-gener
physician interest next-gener tavr devic expect approv
fda next yearboston scientif lotu valv abbott porticoa well farther
horizonboston scientif acur edward lifesci centera valv edward
lifesci centera valv score highest level interest portico acur score
plan adopt new
total physician indic would incorpor new valv practic
weight expect share expect volum physician hospit yield
market share edward abbott
result show high elast demand relat tavr select price
major physician classifi intervent cardiologist
balanc cardiac surgeon cardiothorac surgeon physician
evenli split academ commun hospital-bas practic
distribut physician specialti
distribut hospit type
physician report perform averag procedur per month
across survey particip edward sapien valv use patient
fairli consist market share nation basi physician
use sole edward sapien valv two exclus medtron
market share calcul base expect volum
physician turn case varieti reason
averag physician indic nearli case turn
patient good candid tavr procedur ask best describ
reason procedur perform figur depict reason indic
survey physician believ result bode well futur outlook
tavr indic still patient could benefit earlier detect well
expans low-risk popul
individu turn procedur best describ
reason
sick low elect barclay medic suppli devic
mani physician believ use expand lower risk patient
 today tavr devic approv use patient contra-ind
prohibit risk surgeri well patient deem high surgic
intermedi surgic risk data edward low surgic risk studi
expect releas american colleg cardiolog confer march
believ market expect posit result turn would pave way
label expans low-risk patient ask physician base publicli avail
data pleas provid thought whether believ tavr implant low
risk patient respons depict figur part believ
physician believ tavr use low-risk patient
physician verbatim base publicli avail data pleas provid thought whether believ tavr
implant low risk patient
believ use tavr low risk would prove benefici
especi higher age patient
think good idea gon na work
depend long term studi
think implant low risk patient
robust data shunt perform year
ye select use
avr still gold standard
ye low risk approv
tavr implant low risk patient sinc reserv
long term data promis may equal tradit avr
accept quickli
/prolong live
think horribl idea market dollar appeal
poke groin off-set realiti
opinion worth surgic risk
time yet low risk patient believ data becom
avail approv patient popul within
may advantag avoid savr sternotomi patient
want avoid use anticoagul therefor prefer
biolog mechan valv younger person lifetim sever
tavr could perform
think would interest see compar
surgeri low risk popul
think implant low risk patient without doubt
tavr use low risk patient safe effect
treatment aortic stenosi avoid much morbid
associ surgic aortic valv replac
mani answer need address adopt lower risk
patient multipl question must answer futur regard
stroke valv perform durabl pacemak requir
key metric expans lower risk popul
occur understand trial on-going respect prudenc
dictat get data result hold
intent desir tavr implant low risk patient
believ patient would benefit tavr despit low surgic risk
avoid need prolong hospit sternotomi
physic stress surgeri
think good surgic center surgeri still probabl best low risk
patient recogn tavr potenti becom line
yet
absolut prefer reimburs option low risk
patient avoid mani drawback cabg
surgeri reduc hospit length stay rehab reduc man-hour lost
patient job due recoveri
like approv becom avail low risk patient
age patient like import select process risk
level popul
need studi low risk patienc
ye better surgic valv
definit proport low risk patient get tavr
prove use risk patient faster recoveri time
limit complic
ye think write
patient prefer non-invas approach appropri
believ data indic would increas
believ current evid support good low risk
patient limit long follow data avail
think util subset patient higher risk
select patient current chang
techniqu continu improv
think done well
still think low risk patient savr
ye sinc prefer send patient less invas
data suggest may promis
depend factor
think tavr use low risk patient less invas
savr low risk patient well
need data see patient benefit
absolut question durabl need answer first
excit see data
standard care near futur
tavr excel altern surgeri consid
feel low-risk patient valv
wider rang patient keep mind use less bovin materi
tavr promis futur care select low risk patient
believ everi patient consid avr consid
tavr first undergo savr compel reason
think low risk quick recoveri ideal choic
anyon good anatomi think bioprosthet valv thing
implant low risk patient
better sternotomi
physician alreadi use tavr low-risk patient
ask physician estim percent commerci exclud clinic
studi tavr case risk level find present figur found
intrigu current use low risk surgic patient st score data
combin figur suggest us like addit patient
becom elig tavr procedur upon label expans market may
necessarili see signific step function growth lower risk patient
percent commerci exclud clinic studi tavr case risk level
cumul number tavr procedur perform physician respect
institut total estim sampl averag
physician expect growth volum time period
patient contra-ind prohibit risk high surgic inter-medi surgic risk st score low surgic risk st score barclay medic suppli devic
physician interest emerg technolog
next year half two addit valvesboston scientif lotu valv
abbott porticocould approv use unit state beyond two
addit valvesboston scientif acur edward lifesci centera
valvescould also introduc market ask physician rate scale
level interest use new product result illustr
edward lifesci centera valv score highest level interest
level interest adopt new tavr
level interest adopt new tavr
level interest adopt new tavr
level interest adopt new tavr
somewhat definit interest useno respondentsavg score somewhat definit interest useno respondentsavg score somewhat definit interest useno respondentsavg score somewhat definit interest useno respondentsavg score barclay medic suppli devic
physician will adopt new valv approv
ask physician consid usag abbott portico
lotu valv approv fda price compar exist valv
total physician indic would incorpor new valv practic
remain physician would adopt new valv continu use edward
and/or valv weight expect share expect volum
physician hospit yield market share illustr figur edward
abbott boston scientif simpl averag would yield market
share edward abbott
market share calcul base expect volum
gaug sensit price ask physician rank scale
extent would lower sell price product influenc tavr select averag
score indic us elast demand
extent would lower sell price product influenc tavr select
would use moreno respond barclay medic suppli devic
recent year increas focu use robotic-assist devic
major joint reconstruct first major orthoped manufactur take
major step robot billion acquisit mako decemb smith
 nephew next million acquisit belt januari
zimmer biomet make move juli million acquisit
med-tech sa maker rosa surgic robot lastli depuy synth acquir
orthotaxi undisclos sum februari
receiv fda clearanc expand mako offer includ total knee
applic use triathlon system august compani initi initi
launch earli full roll-out follow full launch
consist grown sever hundr basi point market quarter note
launch cementless knee also help knee growth
manag estim us hospit orthoped practic
approxim half candid least one robot current mako robot
approxim hospit leav ampl room addit growth robot
next sever year number new robot system could
introduc market includ zimmer biomet rosa system js orthotaxi
system zimmer biomet rosa platform expect receiv approv end
begin limit launch johnson johnson orthotaxi platform expect
launch
mako clearli facilit market share gain surpris see
competitor develop robot platform well believ follow survey
help input determin outlook adopt orthoped robotic-assist
procedur impact rosa orthotaxi may ortho-robot market
conduct survey orthoped surgeon gaug current futur
practic pattern particular focu interest level robot physician
practic commun academ medic center
survey conclus stock implic
follow key takeaway orthoped surgeon survey
orthoped survey conclus stock implic
find stock implic
year next orthoped surgeon expect volum total knee total hip arthroplasti
remain strong increas expect respect believ bode
well orthoped manufactur
concentr vendor surgeon concentr use reli one two manufactur product
total hip market share like remain fairli stabl compar
total knee market share project slightli chang owe surgeon
expect alter usag case modestli volume-weight basi
smith nephew net share gainer depuy synth primari donor share
avail usag
surgeon note least one robot facil surgeon report
one robot surgeon robot system surgeon note
use mako robotic-assist system wide avail system
reason use
list sever factor robot cost system score highest
factor behind use robot limit long-term data score lowest
interest new robot
nearli survey respond indic interest newer
system overal view level interest low new system view result
potenti disappoint new entrant like zimmer biomet depuy synth
futur train usag
robotic-assist system
surgeon current use robotic-assist system indic
interest train use robot system next year
project use robotic-
surgeon volume-weight basi expect surgeri perform
tradit approach done robot assist compar
tradit mean robot mako domin
system use one mako futur user current knee user
physician practic commun academ medic center
ask physician estim number total hip knee arthroplasti procedur
perform well expect volum cumul
physician indic expect knee volum increas
physician expect increas hip year increas next
bit surpris level increas project physician estim
faster overal market estim volum increas rang
commun barclay medic suppli devic
survey physician determin vendor manufactur use
total hip total knee arthroplasti system surgeon concentr use
reli one two manufactur product shown figur figur
number hip vendor use physician
number knee vendor use physician
survey result indic hip market share like remain fairli stabl
compar except lose modest share smith
nephew pick share howev note shift attribut mainli
one physician indic his/her long-term sale rep switch manufactur
vendorno vendorno respondentszimm barclay medic suppli devic
figur illustr baselin expect market share manufactur
across surgeon figur list surgeon expect share
usag along rational
total hip arthroplasti market share physician
total hip arthroplasti market share physician chang use
biometstrykerj depuysmith biometstrykerj depuysmith nephewexactechmicroportotherdid give reasoncit explor total hip increas use comfort increasescit rep chang companiescit acti stem barclay medic suppli devic
knee market share expect see slightli shift
survey result indic total knee market share like slightli chang
owe surgeon expect alter usag case modestli
figur illustr baselin market share across surgeon
total knee arthroplasti market share physician
figur highlight surgeon indic expect chang
use along rational includ chang sale rep mako system
innov volume-weight basi smith nephew net share
gainer depuy synth primari donor share
total knee arthroplasti market share physician chang use
biometstrykerj depuysmith nephewexactechmicroportcorinplansto transit strykerdid note reasondid note reasoncom go back use zimmercom shift physician preferencecit makosystem innovationcit fellowship saycit long-term rep chang companiescit increas use given patient demand excel outcomescit impact supplier hospit use complet controldid note reason barclay medic suppli devic
recent year increas focu use robotic-assist devic
major joint reconstruct first major orthoped manufactur take
major step robot billion acquisit mako decemb smith
 nephew next million acquisit belt januari
zimmer biomet make move juli million acquisit
med-tech sa maker rosa surgic robot lastli depuy synth acquir
orthotaxi undisclos sum februari
survey total surgeon note least one robot
facil surgeon report one robot surgeon
robot system surgeon note use one shown figur
shown figur stryker mako wide avail system
total number robotic-assist system avail
use robot none use robot despit one navio smith nephew surgeri barclay medic suppli devic
reason use robotic-assist system
ask surgeon use robot today comment potenti factor
potenti reason behind use robot robot system
score highest cost system second reason
interest futur robot system
next sever year number new robot system could
introduc market includ zimmer biomet rosa system js orthotaxi
system zimmer biomet comment plan approv ofit total knee
applic limit launch though specifi region
launch like occur nevertheless would anticip limit launch us
rel near futur comment orthotaxi system could launch
ask surgeon rate level interest new system
scale result illustr figur nearli survey respond
indic interest newer system
interest level prospect robot system
somewhat definit reasonno respondentslimit long-term data average system average clinic benefit average surgic time average robot hospit average somewhat definit interest useno respondentsrosa zimmer biomet orthotaxi depuy synth tsolut one think surgic barclay medic suppli devic
futur train usag robotic-assist system
ask surgeon current use robot system whether
interest train use surgic robot system next year
indic brought total number surgeon
expect train and/or use robot slightli half surgeon
year see figur view signific shift
surgeon use robotic-assist system total knee
surgeon plan train use robotic-assist
total knee year
project use robot system
ask surgeon project usag robot total knee arthroplasti
procedur increas usag signific volume-weight
basi surgeri expect perform tradit method
done robot assist done robotic-assist
stryker mako domin system use shown figur figur
one mako futur user current knee user
expect use robot total knee arthroplasti
note result weight expect total knee arthroplasti volum
expect use robot total knee arthroplasti
note result weight expect total knee arthroplasti volum
expect penetr robot total knee arthroplasti
valuat methodolog risk
valuat methodolog set price target primarili reli forward price-to-earnings methodolog believ stock
maintain premium multipl given top line bottom line growth prospect pt appli multipl ep
risk may imped achiev barclay research valuat price abbott signific exposur
emerg market given fx rate could pressur ep new product central posit view approv adopt new product
therefor anoth risk risk includ signific reimburs action medic devic product recal fda warn letter
govern regulatori action
valuat methodolog use combin enterpris valu sale price forward earn deriv price target
ev/sal multipl expans current sale estim would impli valuat pe multipl
ep estim discount back rate would impli valuat price target averag two
risk may imped achiev barclay research valuat price risk includ abil compani
sustain least mid-single-digit growth time uptak new product abil realiz cost save target off-set strand cost
chang effect tax rate foreign exchang success deploy capit dilut acquisit
valuat methodolog set price target primarili reli forward price-to-earnings methodolog pt appli
target pe ep estim
risk may imped achiev barclay research valuat price new product import baxter
growth outlook therefor approv uptak new product key risk factor gener competit particularli cyclo
brevibloc could pressur earn and/or extent pressur less expect favor impact fx rate stronger us dollar
could also pressur baxter sale earn outlook risk includ signific reimburs chang fda govern
co
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli
multipl calendar ep
risk may imped achiev barclay research valuat price upsid risk factor extent becton
success integr bard see greater expect revenue/cost synergi downsid fx stronger us dollar commod
cost could greater headwind risk factor includ time success new product increas competit key product
drug-coat balloon infus pump signific chang reimburs fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog believ premium valuat
warrant given believ sustain averag growth profil price target appli pe multipl
ep estim
risk may imped achiev barclay research valuat price new product key sustain
averag growth thu extent product delay approv face increas competit pressur earn stock
pe could pressur risk factor includ signific reimburs chang higher expect product liabil expens fda
govern action dilut associ recent futur acquisit
valuat methodolog use combin ev/sal forward price-to-earnings methodolog set price target
ev/sal approach assum multipl expand would impli target pe approach assum
multipl contract slightli closer peer would impli valuat
risk may imped achiev barclay research valuat price risk includ sustain us
orthoped busi abil maintain mid-singl digit sale growth new product approv competit threat particularli
compani compet larger compani foreign exchang rate higher tax rate fda govern regulatori action
chang hospit capit equip environ
valuat methodolog set price target primarili reli forward price-to-earnings methodolog ew share trade
ep estim believ multipl like compress given slower growth greater competit transcathet valv market
price target appli pe multipl ep estim
risk may imped achiev barclay research valuat price greater tavr sale success tmvr could
result higher earn expand pe risk factor includ new product approv particularli mitral valv competit product
launch signific chang reimburs product failur advers long-term outcom may chang usag trend
product fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog absent confid
acceler core sale growth rate believ market multipl appropri price target appli pe multipl
valuat methodolog risk
calendar ep
risk may imped achiev barclay research valuat price upsid new product drive acceler
sale ep growth downsid less favor trend hospit capital-expenditure slower uptak new product strengthen us dollar higher
tax rate risk includ signific reimburs chang fda product approv time competit pressur fda
valuat methodolog set price target primarili reli forward price-to-earnings methodolog believ share
trade line histor averag price target appli target pe calendar ep estim
risk may imped achiev barclay research valuat price downsid risk includ fx rate
strengthen us dollar could pressur earn stock perform new product key futur success compani
thu extent compani unabl receiv fda approv could advers impact futur outlook upsid greater
success new product margin expans risk includ signific reimburs chang competit pressur product
failur fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target
appli pe multipl ep estim
risk may imped achiev barclay research valuat price fx rate recent acquisit could
pressur earn growth competit pressur particularli area knee competitor launch compet robotic-assist
system could impact growth outlook sentiment toward stock time ultim receipt new product approv could
affect outlook risk includ signific chang reimburs potenti dilut associ acquisit product failur
fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli
pe multipl ep estim
risk may imped achiev barclay research valuat price upsid extent neotract urolift sale
higher expect could drive upsid sale earn lead higher pe downsid urolift sale disappoint core
growth fail improv fx stronger us dollar higher interest rate half debt float risk includ time receipt
new product approv competit pressur particularli key product like urolift signific chang reimburs fda
govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli
market multipl ep estim
risk may imped achiev barclay research valuat price upsid resolut fda matter
acceler top line growth downsid delay new product approv failur see signific increas new product uptak neg
earn revis addit cost associ on-going manufactur issu risk factor includ signific reimburs chang
competit pressur dilut associ potenti acquisit integr acquir busi proce sale busi
fda govern action
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
